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 Due to their prominent role in the orchestration of a broad range of immune responses, 
dendritic cells (DCs) have emerged in the past decade as central target for cancer immunotherapy. 
Recent advance in the knowledge of DCs functions and subset specialization led to the design of 
novel immunotherapeutic approaches based on the possibility to target DCs directly in vivo, thus 
avoiding their ex vivo manipulation. 
A promising strategy is to use antibodies to target antigens to cell-surface molecules expressed by 
DCs, in order to increase T-cell mediated immune responses. The studies performed so far, have 
revealed that the efficacy of in vivo DC vaccination depend on several factors including the specific 
DC subset targeted, their maturation status and the nature and biological properties of the receptor 
targeted. Therefore, the identification of the most appropriate ligand/receptor pairing it is a requisite 
to improve the modality of delivery tumor Ags to DCs. 
To this aim, we screened a library of Ab fragments on mouse DCs to isolate new potential antibodies 
capable of targeting DCs in vivo and able to induce T-cell mediated immune responses against 
specific antigens. In this study, we provide the proof of principle that the phage display technology 
can be successfully used to isolate internalizing antibodies on mouse DCs. We further develop such 
technology by engineering the selected molecules to create antigen fusion proteins to use in 
vaccination protocols. 
In particular, we focus on a high affinity Ab against CD36, a multiligand scavenger receptor 
primarily expressed by the CD8α+ subset of conventional DCs. We characterize the antigen 
presenting properties of this receptor which help to delineate a novel function of CD36 in adaptive 
immunity. We show that targeting CD36 on DCs results in the delivery of exogenous Ags to both 
the MHC class-I and MHC class-II processing pathways. In addition, immunization with the 
recombinant anti CD36-Ag fusion Ab induces the robust activation of naïve CD4+ and CD8+ Ag 
specific T lymphocytes and the differentiation of primed CD8+ T cells into long term effector CTLs. 
Finally, we demonstrate that in vivo targeting of CD8α+ DCs with anti-CD36 Ab elicits humoral and 
cell mediated protection from the growth of an Ag specific tumor. Collectively, these results identify 
CD36 as an appropriate receptor to better elucidate the properties of the lymphoid organ resident 





















1.1  Dendritic cells and the control of immunity 
 Optimal defense against invading pathogens requires specialized classes of non-specific and 
antigen-specific immune responses, generally referred as the innate and the adaptive components of 
immunity. Innate immunity or non-specific host defenses that exist prior to exposure to an antigen, 
specifically detects key features of an infectious process consisting in a limited set of conserved 
molecular patterns (PAMPs) that are unique to the microbial world and invariant among entire 
classes of pathogens (1). PAMPs recognition by immune system has two major effects. First, it 
triggers effector cells of inflammation (macrophages and neutrophils) that limit the infection at the 
site of pathogen entry. Second, it activates antigen presenting cells (APC) to trigger adaptive 
immunity, which increases antigenic specificity and generates immunological memory. 
 Central to this process are dendritic cells (DCs), a heterogeneous family of leukocytes that 
integrate innate information and convey it to lymphocytes. Upon direct recognition of PAMPs 
through specific pattern recognition receptors (PRRs) or indirect sensing of infection through 
inflammatory cytokine or other endogenous “danger” signals, DCs enter an integrated 
developmental program that triggers their differentiation into immunogenic APCs capable of 
priming and sustaining the expansion of naïve T cells. Among the “professional” APCs, DCs have a 
preeminent role in the initiation and modulation of the immune response. Their unique distribution 
and capacity to accumulate within the T cells area of lymphoid organs optimize antigen capture and 
clonal selection of rare CD4+ and CD8+ T cells. Their inherent greater efficiency for antigen 
presentation allows small numbers of DCs and low levels of antigen to induce strong T cell 
responses (2). In addition, DCs have the unique capacity to translate the environmental signals into 
specific classes of adaptive immune responses by polarizing T cells development. Finally, DCs are 
not only implicated in the induction of immunity, but also play an essential role in the generation of 
both central and peripheral T cells tolerance by inducing deletion, anergy or regulation of T 
lymphocytes. 
 
1.1.1 The “Langerhans cells Paradigm” 
 Dendritic cells are described as following a life cycle that was modeled according to 
observations of studies carried out in the 1970s and 1980s by Steinman and colleagues on DCs 
found in the epidermis (Langerhans cells) and on DCs purified from the spleen (3). This model, 
generally referred as “Langerhans cells paradigm”, proposes that DCs can exist in two functional 
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states: immature and mature. In the periphery, immature DCs efficiently take-up self and non self 
antigens but are quite inefficient in presenting it to T cells. Only upon encounter of pathogens and 
mediators of inflammations, DCs enter an integrated developmental program called maturation. 
During this process, they downregulate their endocytic capacity, activate the antigen processing 
machinery that generates complex of MHC molecules with peptides derived from the internalized 
antigens and increase the expression of T cell co-stimulatory molecules. In parallel, modifications in 
the pattern of chemokine receptors and adhesion molecules and changes in the cytoskeleton 
organization cause the mobilization from the periphery to secondary lymphoid organs where the 
antigen are efficiently presented to T cells thus initiating adaptive immune responses. 
 Important findings of the last few years have revealed a far greater complexity of the DCs 
system of APCs with the consequent need to add few modifications to this original DCs life cycle 
paradigm. The analysis of the DCs found in the thymus, spleen and lymph nodes has revealed a 
considerable heterogeneity and has led to the definition of several DCs subtypes, each with a 
particular location and specialized function in the immune system (4). It is now clear that only a 
fraction of the DCs found in lymph nodes are derived from cells previously resident in the peripheral 
tissues. In a steady state condition (i.e in absence of infections or inflammatory stimuli), half of the 
DCs found in lymph nodes and most of the DCs in the spleen seem to be lymphoid tissue resident 
cells, with an immature phenotype and great efficiency in antigen uptake and processing (5, 6). 
Therefore, these lymphoid-organ-resident DCs do not conform to the Langerhans cells paradigm, 
since they develop from bone marrow precursors within the lymphoid organs and without previously 











Figure I. Different life cycles of migratory 
and resident dendritic cells. Migratory DCs 
have an immature phenotype in peripheral 
tissue where they survey the environment and 
endocytose extracellular material. They 
migrate through the afferent lymph to the local 
lymph nodes where they acquire a mature 
phenotype. Resident DCs, present in lymph 
nodes and spleen, spend their entire lifespan in 
an immature state unless they encounter 
pathogen products or inflammatory signals, 
which cause their maturation in situ. 
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1.2  Dendritic cells general features 
1.2.1 Mechanisms of Antigen uptake and pathogen recognition 
 Dendritic cells have evolved several features that greatly enhance their capacity as APCs. 
Among these, the property of immature DCs to efficiently take up particles and microbes by 
phagocytosis and the ability to form large pinocytic vesicles to sample extracellular fluids and 
solutes in a process referred to as macropinocytosis (8). Moreover, DCs express a great variety of 
receptors involved in antigen recognition and uptake by mechanisms of receptor mediated 
endocytosis. Endocytosis is a regulated process in DCs, being highly active in immature DCs and 
downmodulated upon cells maturation (9). This assures the efficient sampling of the environment in 
the periphery and concomitantly limits the range of antigens that the cells will be able to present 
after living the peripheral tissues. The downregulation of internalization is achieved by decreasing 
the expression of the cell receptors involved in antigen uptake and by downmodulating both 
macropinocytic and phagocytic activities. 
 
Phagocytosis 
 The uptake of large particulate antigens (>0,5µm) by phagocytosis is the prevalent form of 
antigen uptake in vivo for both pathogen-derived and endogenous antigens (8). It is an active and 
highly regulated process initiated by the engagement of specific cell surface receptors, generally 
involved also in clathrin mediated endocytosis, that trigger a signaling cascade mediated by the Rho-
family GTPases (Rho, Rac and Cdc42). The final outcome is the extensive reorganization of the 
actin cytoskeleton with the formation of cell-surface extensions that zipper up around the pathogen 
to engulf it (10). The nature of the particle to be ingested and the receptors that recognizes it 
determine the mode of protrusive activity and the signaling pathways that are activated. In the case 
of FcγR mediated phagocytosis, the cells extends pseudopods that engulf the particle and 
subsequently fuse to form a phagosome. This process requires the activation of Cdc42 for the 
pseudopods extension and Rac in pseudopods fusion and phagosome closure. In contrast, 
phagocytosis mediated by complement receptor is controlled by Rho, do not induce pseudopod 
formation but requires the coordinated action of chemokines and integrin ligation to form the 
phagocytic cup (11). 
 Phagocytosis is essential in host defense against infections: immature DCs were reported to 
phagocytose almost any kind of bacteria, both GRAM+ and GRAM- and mycobacteria, yeast cells 
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and parasites (12). Phagocysis is also crucial for clearing apoptotic cells, both at sites of 
inflammation and tissue damage and during development. This process is mediated by the 
recognition of specific molecules that are normally absent on live cells such as calreticulin and 
phosphatidylserine, amino sugars and lysophospholipids and involves various types of scavenger 
receptors, complement receptors and integrins on DCs. The nature of the cargo determines the set of 
receptors involved in its recognition and uptake, the signaling cascade that is activated upon receptor 
binding and ultimately regulates the efficiency of processing/presentation and the immunogenicity of 
the internalized material. For instance, phagocytosis of microbial cells and of apoptotic bodies rely 
on the same phagocytic machinery, but the cellular responses that accompany these forms of 
phagocytosis are different, being respectively inflammatory with the production of tumor necrosis 




 Macropinocytosis contributes to bulk fluid-phase uptake via the formation of membrane 
protrusions that collapse onto and fuse with the plasma membrane generating large endocytic 
vesicles (micropinosomes) that allow the sampling of large volumes of extracellular milieu (10). The 
signaling cascades that induce macropinocytosis involve the Rho-family of GTPases and especially 
Cdc42, that trigger the actin-dependent formation of the membrane ruffles (11). In immature DCs 
macropinocytosis is constitutive and like phagocytosis, is downmodulated upon cells maturation. 
The impact of antigen uptake via macropinocytosis is vivo is not clear since pathogens release few 
soluble antigens, with most proteins integrated in membranes, cell walls or cytoplasmic 
compartments that would need to be taken up as particles. Conversely, it has a role in the capture of 
soluble antigens that become available upon intravenous, intraperitoneal and intradermal injections 
(8). The degree of internalization of fluid-phase antigens is proportional to their concentration in the 
medium. The efficiency of endocytosis is increased by non-specific binding of solutes to the cell 
membrane (adsorptive pinocytosis) and even more by the capture of soluble antigens through 
specific high affinity receptors (receptor mediated endocytosis) that are concentrated into specialized 







Receptor mediated endocytosis 
 Uptake of extracellular material through receptor mediated endocytosis greatly increases the 
efficiency of antigen capture thus allowing DCs to present antigens found at picomolar and 
nanomolar concentrations (2). This process is initiated by signal cascades triggered by specific 
endocytic receptors present in specialized regions of the plasma membrane. The nature of the 
receptors engaged determines the mechanism of internalization that can be mediated by clathrin-
coated vesicles, by caveolae or can be both clathrin- and caveolae- independent.  
DCs express a wide range of endocytic receptors that belongs to different families. Receptors for the 
Fc portion of immunoglobulin (FcRs) and complement receptors (CRs) are involved in the uptake of 
particles that are opsonized by immunoglobulins or complement factors. A second class of endocytic 
receptors comprises scavenger receptors (SRs) and C-type lectin family receptors (CLRs) that 
directly recognize specific structures on both self-antigens and pathogens and are generally referred 
to as innate immunity receptors. A large number of these endocytic molecules are selectively 
expressed by subpopulations of DCs thus contributing to the functional diversity among different 
DCs. 
 
Fcγ and complement receptors 
 Mouse immature DCs express different types of FcRs such as FcγRI, FcγRIIb, FcγRIII and 
FcγRIV and the complement receptors CR3 and CR4. Both FcRs and CRs may be functionally 
considered as antigen receptors due to their ability to bind and to mediate the uptake of immune 
complexes and complement-opsonized particles. The FcγRs differs in terms of antibody isotype 
specificity and binding affinity with FcγRI binding with the highest affinity exclusively monomeric 
IgG2a and FcγRIV binding with intermediate affinity IgG2a and IgG2b but not IgG1, whereas both 
FcγRIIb and FcγRIII binds immune complexes of all IgG isotypes (14). Antigens bound to soluble Ig 
can follow different fates depending on the cell type that captures them. Among APCs, DCs are 
unique for their capacity to efficiently deliver antigens internalized via FcγRs to the antigen 
processing machinery which results in the formation of both MHC class I and MHC class II-peptide 
complexes (15). 
CR3 binds a promiscuous range of ligands, both of host and microbial origin. It was shown to be 
involved in the uptake of complement opsonized apoptotic cells and also in the direct recognition of 






C-type lectin receptors 
 Immature DCs differentially express a broad variety of C-type lectin receptors (CLRs) that 
are involved in the recognition of a wide range of carbohydrate structures in antigens and act as 
endocytic or phagocytic receptors depending on the size of the antigen. The most characterized 
examples of DCs CLRs include the mannose receptor, DEC205, DC-SIGN, Dectin-1 and -2 and 
Langerin. They are generally classified as type I or type II receptors depending on the orientation of 
their N terminus, which is extracellular or cytoplasmic respectively, and on the number of 
carbohydrate recognition domains (CRDs) present in their extracellular portion. The cytoplasmic 
domains of the CLRs are diverse and contain several conserved motifs that are important for antigen 
uptake and determine the intracellular route followed by the antigen upon receptor-mediated 
internalization. For instance, most CLRs (DEC205, DC-SIGN, BDCA-2 and Dectin-1) contain a tri-
acidic cluster that target internalized antigens to lysosomes and MHC class II+ late endosomes, 
whereas the MR constitutively delivers antigens to early endosomes and rapidly cycle back to the 
cell surface (17). 
Several CLRs expressed by immature DCs are capable of binding pathogens through the recognition 
of specific carbohydrate structures present on the cell wall component. Some CLRs have 
overlapping carbohydrate specificity and recognize a wide variety of carbohydrate structures such as 
mannose- and fucose-containing carbohydrates, yet others have a unique recognition profile dictated 
by a specific branching of the mannose structures (17). However, little is known about the antigen 
specificity of CLRs expressed by DCs and their functions are not yet documented. Only in few cases 
specific pathogens have been associated to CLRs. For example, the mannose receptor is able to bind 
yeast, human immunodeficiency virus and Micobacterium tuberculosis, whereas DC-SIGN binds a 
large variety of pathogens, including viruses (HIV, HCV, CMV, Ebola and Dengue virus), Candida 
albicans, bacteria (Micobacterium tuberculosis, Helicobacter pylori and Klebsiella pneumonae) and 
parasites (Leishmania pifanoi and Schistosoma mansoni) (18). Dectin-1 recognizes conserved 
molecular pattern (β1,3-glucans) in fungal pathogens (P.carinii, C.albicans and A.fumigatus) and 
triggers a signaling pathway that induces the activation of adaptive immunity (19). To date this is the 
only documented case of host protection mediated by a CLR. In fact, although DC-SIGN and MR 
mediate the uptake of pathogens, this rather represents a mechanism exploited by the pathogen itself 
to favor its survival and to escape immune activation (18). Therefore, further analysis will be 
required to clarify the role of CLRs in protection from invading pathogens (20). 
In addition, some CLRs were shown to mediate the uptake of host derived molecules. For example, 
MR-deficient mice were shown to have increased plasma concentration of endogenous 
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glycoproteins, such as lysosomal hydrolases (21) and lutotropin (22) confirming an important role 
for this CLR in the clearance of self antigens. 
 
Scavenger receptors 
 A third class of endocytic receptors expressed by DCs is the family of scavenger receptors 
(SRs). SRs encompass a broad range of cell-surface glycoproteins that differ greatly in their 
structure but are, by definition, all capable to mediate the uptake of selected polyanionic ligands, 
including modified low-density lipoproteins (LDL). The main feature of SRs is their ability to 
recognize multiple ligands, both microbial and host derived, and to carry out a multiplicity of 
cellular functions (ranging from anti-microbial immunity, antigen presentation and cell adhesion to 
atherosclerosis and Alzheimer’s disease). However, while SR expression and function has been 
extensively investigated for macrophages, the role of these molecules on DCs is only beginning to be 
unraveled. Three SRs belonging to different classes, defined on the basis of their molecular 
structure, are expressed by DCs: Scavenger Receptor A (SR-A) (23), CD36 (24-26) and Lox-1 (27). 
 SR-A is a trimeric type II glycoprotein containing in the extracellular portion an α helical 
coiled coil, a collagenous and a C-terminal cysteine-rich domain. Its cytoplasmic tail instead, 
contains a potential protein kinase C interaction site, but not an internalization motif. SR-A was 
shown to bind several components of both GRAM- and GRAM+ bacteria (lipid A and lipoteichoic 
acid respectively). Indeed, its role in microbial clearance has been confirmed in two studies 
performed on SR-A deficient mice, where the absence of the receptor resulted in increased bacterial 
loads of Listeria monocytogenes and Staphylococcus aureus (28). Recently, Amiel et al showed that 
SR-A-/- BMDCs are impaired in their ability to phagocytose and accumulate E.coli bacteria and that 
the internalization requires lipid raft structures (29). Similarly to other SRs, SR-A recognizes also 
endogenous ligands and modified host molecules expressed on aged/apoptotic cells, with a possible 
role in tissue homeostasis (30). Finally, Berwin et al identified SR-A as a predominant endocytic 
receptor for the ER chaperones gp96 and calreticulin and demonstrate that SR-A can direct gp96-
OVA derived peptide complex into an MHC class I presentation pathway (31). However, SR-A is 
not required for antitumor immunity generated by HSP-based vaccines, rather its lack restored the 
immunogenicity of poorly immunogenic tumors and enhanced the tumor specific immune response, 
suggesting a role of SR-A in immune suppression and in the maintenance of host immune 
homeostasis (32). 
 LOX-1 is a 48-50 kDa type II membrane glycoprotein with a C type lectin-like domain 
whose antibacterial potential was revealed by binding studies performed with both GRAM+ and 
GRAM- bacteria (S. aureus and E.coli). LOX-1 was also identified as a receptor for Klebsiella 
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pneumoniae OmpA, a major component of the outer membrane of Enterobacteriaceae. Specifically, 
it was shown to act in a sequential and coordinate way with TLR-2 to mediate OmpA internalization 
and DCs activation (33). Delneste et al first reported LOX-1 as a receptor for Hsp70 on human DCs 
and showed its involvement in Hsp70 mediated antigen cross-presentation in vivo thus suggesting a 
possible role for LOX-1 in the recognition of cellular damage (27). 
 CD36 belongs to the class B SR family. It is a double-spanning N-linked glycosylated protein 
of 53 kDa thought to be associated with lipid rafts. The predicted structure orients most of the 
protein extracellularly, except for two short (9-13 amino acids) cytoplasmic tails (34). The C-
terminal cytoplasmic domain was shown to have a role in the localization of CD36 in the plasma 
membrane and in the uptake of long-chain fatty acid (35) and oxidized LDL (OxLDL) (36). Binding 
of OxLDL to CD36 leads to endocytosis through a lipid raft pathway that is both clathrin and 
caveolin independent (37). 
As most of SRs, CD36 is a multiligand receptor shown to play a role in diverse cellular processes 
including foam cell formation, fatty acid transport, suppression of angiogenesis, cell-matrix 
interaction (34). CD36 is one of the first DCs receptors shown to be involved in the uptake of 
apoptotic cells (24), probably through interactions with oxidized phosphatidylserine (38) and with 
thrombosponsdin-1 (39) present on the membrane of apoptotic cells. 
CD36 has also been implicated in the innate immune response to GRAM+ bacteria such S. aureus . 
Hoebe et al first demonstrated the selective and nonredundant role of CD36 as sensor for microbial 
diacylglycerides such as macrophage-activating lipopetide 2 and lipoteichoic acid (LTA) (40). Upon 
binding to bacterial LTA, CD36 forms a cluster with the heterodimer TLR2/TLR6 within lipid raft, 
followed by the internalization of the complex and its targeting to the Golgi apparatus (41). The C-
terminal cytoplasmic residues of CD36 were shown to be essential to trigger phagocytic engulfment 
and specifically, the tyrosine 463 was implicated in signaling to the actin cytoskeleton (42). These 
data collectively indicated that CD36 acts as a facilitator or co-receptor for diacylglyceride 











1.2.2 Mechanisms of Antigen presentation and cross-presentation 
 After their entry into DCs, antigens are degraded into small immunogenic epitopes that 
associate with the major histocompatibility complex molecules (MHC) and are transported to plasma 
membrane where they eventually trigger the activation of naïve T lymphocytes. 
Specifically, the activation of CD8+ and CD4+ T lymphocytes requires recognition by the T cell 
receptor (TCR) of fragments of antigens (peptides) associated with MHC class I and MHC class II 
molecules, respectively. The antigen processing pathways that lead to the formation of peptide-MHC 
complexes, rely on ancient proteolytic mechanisms (proteasome, lysosomes) that in DCs were 
geared towards optimal T cells stimulation (8). 
Initial studies on antigen presentation defined a strict compartmentalization of MHC class I and II 
biogenensis, with MHC class II molecules encountering exogenous antigen in the endocytic pathway 
and MHC class I loading with endogenous antigens in the endoplasmic reticulum (ER). Although 
still valid, recent evidence have proved that both boundaries can be crossed and so MHC-II 
molecules can present intracellular antigens not coming from extracellular space and MHC-I can 
present peptides derived from exogenous antigens, phenomenon generally referred to as cross-
presentation. 
 
MHC class I–restricted antigen presentation 
 DCs process and present on MHC class I molecules proteins coming from various sources 
including cytosolic proteins (either endogenous or viral), alternative translation products and 
defective ribosomal products (DRiPs), protein retrotranslocated to the cytosol from the ER (i.e. 
secretory and membrane proteins) and internalized proteins transferred to the cytosol and imported 
into the ER (8). Independently of the route of entry, most of the peptides to be loaded on MHC-I 
molecules are generated by the proteasome and further trimmed by cytosolic or ER resident 
peptidases. The proteasome has a critical role in initiating the processing and in most cases, releases 
precursor peptides that have the correct C terminus for MHC-I anchoring and an N-terminal 
extension that requires further degradation. The efficiency and rate of epitope generation by the 
proteasome are increased in response to an inflammatory environment (i.e. IFN-γ) by expression of 
facultative subunits (referred to as immunosubunits). The proteasome has also been implicated in 
splicing of peptides to create epitopes from sequences that are not contiguous in the original protein 
(43, 44). The N-terminal trimming occurs in both cytosol and ER by the tripeptidyl peptidase II 
(TPPII) and ER-associated aminopeptidase (ERAAP) respectively (45). Once the peptide products 
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are shuttled into the ER via the transporter associate with antigen processing (TAP) and customized 
by ERAAP, the final MHC-I peptide complex (pMHC-I) is formed and eventually displayed on the 
cell surface (46). 
 
Cross-presentation of exogenous antigens 
 Dendritic cells have evolved a specialized machinery that allows the entry of exogenous 
antigens into the MHC class I pathway of antigen presentation (47). This unique capacity, generally 
referred to as “cross presentation,” is a major mechanism for the immune surveillance of tissues, 
allowing the immune system to monitor parenchymal cells for the presence of foreign antigens.  
Several types of antigens have been reported to be cross-presented: soluble proteins, immune 
complexes, pathogens and cellular antigens, independently of the mechanism of internalization 
(macropinocytosis, phagocytosis or receptor mediated endocytosis) (48). However, the mechanisms 
by which APCs transfer internalized antigens to the MHC class I loading pathway are not well 
understood (49). In most of the cases, proteasomal digestion and transport into ER by TAP seem to 
be required, implicating a mechanism to allow the release of the antigen from the endocytic 
structures to the cytosol. However, the cellular and molecular bases of endosomal egress into the 
cytosol remain unknown (49). Reports have suggested that a potential mechanism for cross-
presentation relies on the provision of MHC-I loading components to the phagosome by membranes 
derived from the ER, resulting in ER-phagosome complexes self-sufficient for cross-presentation 
(50, 51). Although the relative contribution of the ER versus the plasma membrane as source of 
membrane for phagocytosis is still a matter of debate (49), recent data by the Cresswell group have 
shown that soluble antigens can gain access to the lumen of the ER after internalization (52) and that 
the ER protein retrotranslocation machinery (ERAD) is involved during cross-presentation (53). 
Among APCs, DCs have the highest cross-presentation efficiency. One of the mechanisms that 
accounts for this specialization is the limited degradation of internalized antigens in the endocytic 
compartments, which may increase the opportunity for the internalized antigens to reach the cytosol 
(54). Indeed, experimental reduction of lysosomal proteolysis by choloquine was shown to increase 
the efficiency of cross-presentation (55). Moreover, recent findings by Savina et al propose the 
NADPH oxidase NOX2 as a key regulator of the DC phagosome pH. Recruitment of NOX2 to 
immature DC phagosomes causes their active alkalinization and is required for efficient antigen 
cross-presentation to CD8+ T cells (56), further supporting the evidence for a unique lysosomal 
compartment in DCs. 
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The uniqueness of DCs with respect to antigen handling reflects the essential role that these cells 
play in priming in vivo CTL responses to exogenous antigens. In an elegant study, Jung and 
colleagues demonstrated that the in vivo depletion of DCs abrogates priming of CD8+ T cells by 
exogenous cell-associated antigens and results in the failure to mount a CTL response to infection 
with the intracellular bacterium Listeria monocytogenes and the malaria parasite Plasmodium yoelii 
(57). In addition to intracellular bacterial infection, cross-presentation have an essential role in 
responses to those viruses, e.g. cytopatic strains or ones with immune evasion molecules, that impair 
the ability of directly infected DCs to function, or to tissue specific viruses that do no infect DCs 
(58-61). Finally, cross-presentation is also implicated in the maintenance of both central and 
peripheral tolerance to self antigens eventually leading to the deletion or anergy of self reacting 
CTLs (62). 
 
MHC class II–restricted antigen presentation 
 Antigens loaded on the MHC-II are typically exogenous proteins that are internalized by DCs 
through different mechanisms of endocytosis or endogenous proteins that reside in the secretory 
system. Moreover, analysis of the peptides eluted from the MHC-II molecules has revealed that also 
antigens topologically isolated from the endosomal system (i.e. cytosolic and nuclear proteins) can 
gain access to MHC-II class antigen presentation pathway (63). Recent studies have implicated 
autophagy as likely source of peptide derived from various cytosolic and nuclear antigens (64). 
Schmid and colleagues have recently shown that macroautophagy is a constitutively active pathway 
in all MHC-II positive cells and that autophagosome continuously fuse with multivesicular MHC-II 
loading compartments. They also show that targeting antigens to autophagosomes leads to enhanced 
MHC-II presentation and CD4+ T cells stimulation (63). 
De novo synthesized MHC-II αβ dimers assemble in the ER with the chaperon invariant chain (Ii), 
which inserts its class II associated peptide (CLIP) portion within the peptide binding site thus 
stabilizing and protecting the MHC-II dimer from other polypeptides. The MHC-II αβIi complexes 
are transported to early endosomes and further on to late endosomes and lysosomes. Along this 
pathway, the Ii is progressively processed by various proteases (AEP, cathepsins B and S) and 
finally displaced to allow the binding of the antigenic peptide, in a reaction favored by the acidic pH 
and by the chaperone protein HLA-DM (8). MHC-II molecules can bind polypeptide precursors that 
are trimmed by various proteases along the endocytic route, so that the final MHC-II peptide 
complex eventually reaches the plasma membrane. 
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Recent findings by Blander et al have demonstrated how the nature of the cargo internalized by 
phagocytosis and thus the type of receptors engaged during this process are able to influence the 
efficiency of presentation on MHC class II molecules. They show how the generation of peptide-
MHC class II complexes is controlled by Toll-like receptors (TLRs) by regulating the progressive 
proteolysis of the Ii to CLIP in a strictly phagosome-autonomous manner. This mechanism allows 
DCs to distinguish between different forms of antigens as self or non-self at the subcellular level and 
ensures that only antigens that concomitantly engage TLRs are preferentially delivered to the pool of 





Figure II. The antigen-presentation pathway in dendritic cells. MHC class I molecules present 
peptides that are primarily derived from endogenously synthesized proteins of either self of pathogen 
origin. These proteins are degraded into peptides by the proteasome and transported through TAP 
molecules into the endoplasmic reticulum for loading on MHC class I molecules. MHC class II 
molecules acquire peptide cargo that is generated by proteolytic degradation in endosomal 
compartments. The precursor proteins of these peptides include exogenous material that is endocytosed 
from the extracellular environment, and also endogenous components, such as plasma membrane 
proteins and cytosolic proteins that access the endosomes by autophagy. 
DCs have the unique ability to present peptides derived from exogenous proteins on MHC class I 
molecules (cross-presentation), although the mechanism involved in this pathway is still poorly 
understood. The bifurcated arrow indicates that the MHC class II and MHC class I cross-presentation 
pathway may “compete” for exogenous antigens, or that the endocytic mechanism involved in the 
internalization of a given antigen may determine whether it is preferentially delivered to the MHC class 
II pathway or the MHC class I cross-presentation pathway. 
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1.2.3 Induction of Dendritic cells activation and signal transduction 
 Only upon direct recognition of pathogens associated pattern (PAMPs) or sensing of 
inflammatory signals, DCs are activated to enter the program of maturation that endows the cells 
with the ability to stimulate naïve T lymphocytes. DCs response to microbial/inflammatory signals is 
mediated by different classes of surface and intracellular receptors whose engagement triggers signal 
cascades that lead to the production of inflammatory cytokines, to the up-regulation of co-
stimulatory molecules and to the altered expression of chemokine receptors profile. Mature DCs 
have an increased antigen-presenting capacity and migrate to the draining lymph nodes where they 
interact with and stimulate antigen specific T cell. DCs maturation is therefore a critical link between 
innate and adaptive immunity (65). 
 
Toll like receptor family 
 One of the best characterized classes of pattern recognition receptors (PRRs) that directly 
contribute to the inflammatory response to pathogens is the Toll-like receptor family (TLRs). 
Mammalian TLRs are a family of at least 12 transmembrane proteins that collectively recognize 
lipids, carbohydrate, peptide and nucleic-acid structures broadly expressed by different groups of 
micro-organisms. Some TLRs (TLRs 1,2,4,5 and 6) are expressed at the cell surface and seem to 
specialize in the recognition of mainly bacterial products, whereas others (TLRs 3,7,8, and 9) are 
expressed on the membrane of endocytic vesicles or other intracellular organelles and are specialized 
in detection of viral nucleic acids (66). TLRs differ from each other in ligand specificities, 
expression patterns and presumably in the target genes that they can induce. 
TLR4 plays an essential role in the recognition of LPS, a major component of GRAM- bacteria, 
whereas TLR2 is critical to the recognition of bacteria peptidoglycan and lipoproteins, but it is also 
able to recognize components from fungi (zymosan) and parasites (glycoinositolphospholipids from 
Trypanosoma Cruzi). TLR2 promiscuity in ligand recognition derives from its ability to cooperate 
with other TLRs (TLR1 and TLR6) by formation of different heterodimers which confer 
discrimination among different microbial components (67). Further complexity is added by recent 
data showing the involvement of non-TLRs in the presentation of some PAMPs to TLR2. For 
instance, the scavenger rector CD36 acts as facilitator to mediate the interaction of microbial 
diacylglicerydes to the heterodimer TLR2/6 (40). Moreover, the potential interaction of TLR2 with a 
member of CLRs is suggested by data from Wang et al. showing the critical role of TLR2 in the 
initiation of the adaptive immune response to the polysaccharide A (PSA) from Bacteroides fragilis 
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(68). Other TLRs are involved in the recognition of microbial proteins such as flagellin by TLR5 or 
apicomplexan profilins by TLR11 (69). 
TLRs have also an essential role in the antiviral immune responses due to their ability to induce type 
I IFNs, a family of cytokines specialized to coordinate immunity to viruses and other intracellular 
infections (70). For instance, TLR9 and TLR7 which represent a structurally related subfamily, are 
involved in the recognition of unmethylated 2’-deoxyribo (cytidine-phosphate-guanosine) (CpG) 
DNA motifs present in bacteria and viral DNA, or ribonucleic acid homologs (imiquimod and 
resiquimod) and synthetic ssRNA rich in guanosine/uridine respectively. A further member, TLR3, 
responds to dsRNA and to its synthetic analog poly-inosinic acid-cytidylic acid (poly(I)●poly(C)) 
(71). 
Upon recognition of their ligands, TLRs transduce signals through two pathways involving distinct 
adaptor proteins containing Toll/IL-1R (TIR) domains. One of these adaptors, MyD88, is utilized by 
all of the known TLRs except TLR3. MyD88 is recruited to the receptor-ligand complex in an 
interaction that is mediated its C-terminal TIR domain. Through its N-terminal domain the adaptor 
engages the kinase IRAK which is activated by phosphorylation a then associates with TRAF6, 
leading to the activation of two distinct signalling pathways: JNK and NF-kB (72). 
TLR3 and TLR4 are able to activate NF-kB in a MyD88 independent way that involves the adaptor 
molecule TRIF and other signalling molecules such as RIP1 and TRAF6. Activation of TLR3 and 4, 
through the adaptor TRIF, induces also the production of type I IFN. TRIF associates with the 
kinases TBK1 and IKKi which mediate the phosphorylation and the nuclear translocation of IFN-
regulatory factor 3 (IRF3) (73). Also TLR7, 8 and 9 elicit type I IFN induction, especially IFN-α, 
through MyD88, in a pathway that involve the kinase IRAK and the IFN-regulatory factor 7 (IRF7) 
(73) 
Collectively, activation of these signalling cascades induce the expression of a variety of host 
defence genes that include inflammatory cytokines (IL-12, TNFα and IL-6) and type I interferon 
cytokines, the up-regulation of co-stimulatory molecules (CD40, CD80 and CD86) and the altered 
expression of chemokines receptors (CCR2, CCR 5 and CCR7) (65). 
TLRs ligands are also able to signal an array of responses that affect the membrane vacuolar system, 
the cytoskeleton and the machinery involved in antigen processing and presentation (74). One of the 
earliest responses triggered by TLRs ligands in DCs is the transient increase in macropynocytosis 
(74) and phagocytosis (75) probably through the activation of signalling pathways that regulate the 
actin cytoskeleton (74). Moreover, the simultaneous exposure of the antigen with LPS, the ligand of 
TLR4, enhances antigen presentation on MHC class I molecules (74) and favor peptide-MHC class 
II generation within TLR-signalling phagosomes (13). Finally, LPS signals a shut-down of peptide-
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MHC class II endocytosis, thus extending the half-life of assembled peptide-MHC complexes at the 
plasma membrane (76). 
 
Fc receptor family 
 Some classes of PRRs involved in antigen recognition and uptake are also able to activate a 
downstream signalling cascade that leads to DCs maturation. Among these, the well characterized 
class of Fcγ receptors. The potent immunoregulatory functions of immune complexes (ICs) rely on 
two different classes of DCs FcγRs: the activatory FcγRIII and FcγRIV and the inhibitory receptor 
FcγRIIb that transduce their signals via immunoreceptor tyrosine-based activation (ITAM) and 
inhibitory motifs (ITIM), respectively (14). 
FcγRIIb is a single-chain receptor that carries an ITIM motif in its cytoplasmic domain. Its 
expression on DCs controls ICs mediated DCs maturation, as DCs derived from mice deficient for 
FcγRIIb have an enhanced potential to generate Ag-specific T cells responses (77). FcγRIIb may 
function as a regulator of DCs activation by setting the threshold that prevents spontaneous 
maturation of DCs and thus promoting steady-state tolerance (14). 
The activating FcγRs transmit their signals through a common accessory γ chain that carries the 
ITAM motif and that is essential for their cell surface expression. DCs maturation is triggered by 
FcγRs engagement in a signalling pathway that leads to tyrosine phosphorylation of the ITAM motif 
by members of the Src-kinase family and subsequent recruitment of members of the Syk-kinase 
family (78). 
The paired expression of activating and inhibitory FcγRs on the same DCs is the key for the 
generation of balanced immune responses, where the final outcome will depend on the expression 
levels of activating and inhibitory receptors, on their relative affinity for IgGs and on the isotype of 
the antibodies produced by the humoral response. 
 
C-type lectin receptor family 
 Among C-type lectin receptors, Dectin-1 is the first example of PRR that can mediate its own 
intracellular signals thus coupling PAMP recognition to the induction of adaptive immunity. Dectin-
1 contains an ITAM-like motif in its cytoplasmic tail which resembles sequences found in the 
activating FcγRs and similarly to them, upon receptor engagement, it is phosphorylated by Src-
kinases and subsequently it recruits Syk-kinases (79). The tyrosine kinase Syk activates downstream 
signalling components including the transcription factor NF-kB in a pathway that also involves the 
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CARMA1-related adaptor protein CARD9. Dectin-1 signalling in DCs results in maturation and 
production of a distinct combination of cytokines, including IL-2, IL-10, TNF and IL-23 which 
strongly biased T helper cell differentiation to a T helper 17 fate (19). 
 
Intracellular pattern recognition receptors 
 In addition to membrane associated PRRs, DCs expresses cytosolic receptors involved in the 
recognition of bacteria and viruses that gain access into the cytoplasm and are able to induce the 
production of cytokines and cell activation. These cytosolic receptors are grouped in two main 
family: the NLRs (nucleotide-binding oligomerization domain (NOD)-like receptor family) which 
comprises at least 23 members that are either NOD receptors or NALPs; and the RLRs (RIG-I like 
receptors), a family of receptors that have an RNA-helicase domain joined to two caspase-
recruitment domains (CARDs) which include RIG-I (the retinoic-acid inducible gene I) and MDA5 
(the melanoma-differentiation-associated gene 5) (80). NLRs are involved in the recognition of 
bacterial peptidoglycans from both GRAM+ and GRAM⎯ bacteria and drive the activation of MAP 
kinases and NF-kB in a signalling pathway similar to that triggered by TLRs. In addition to 
microbial products, some NALP proteins can also sense the presence of host danger signals such as 
low concentrations of intracellular potassium, monosodium urate and calcium pyrophosphate 
crystals and drive the formation of a complex called “inflammasome”. This complex has an 
important role in the activation of pro-inflammatory caspase such as caspase-1 which in turn leads to 
the processing and the release of the active form of the inflammatory cytokine IL-1β. RLRs are 
cytoplasmic sensor of virally derived dsRNA and similarly to anti-viral TLRs trigger the activation 
of NF-kB and transcription factors of the IRF family (IRF3 and IRF7), which cooperate in the 
induction of antiviral IFN type I (81). 
 
 Microorganisms are thus able to simultaneously trigger a complex set of PRRs, both within 
and outside the TLRs family. It is becoming clear that the combined activation of these different 
receptors can result in complementary, synergistic or agonistic effects especially in terms of cytokine 
production (81). Not only the combination, but also the order in which the stimuli are delivered over 
a defined period of time is crucial to determine the overall outcome of the response. DCs activation 
can be viewed as a dynamic system that continuously adjust transcriptional activity depending on the 
detection of different stimuli and enables the integration of multiple signals in a defined temporal 


















Figure III. Schematic representation of the main signaling pathways of the PRR families. Only 
the adaptor molecules and the main signaling pathways that differentiate the different classes of PRRs 
are shown. In reality, the pathways that are activated by the different receptors are multiple. TLRs 
(with the exception of TLR3), IL-1R and IL-18R induce NF-kB dependent cytokine production 
through a pathway involving the adaptor MyD88. However, TLRs signaling may also involve MAP 
kinases and phosphatidylinositol 3-kinase. TLR3 and TLR4 uses a MyD88-independent signaling 
pathway that involves the adaptor molecule TRIF and induces type I IFNs production. Dectin-1 (a β-
glucan) receptor is shown as an example of various cell-surface PRRs, that like FcRs, signal via their 
ITAM-like motif to activate the kinase SYK. The NLRs family of intracellular PRRs signal through 
complex pathways that result in the activation of caspase-1 in case of NALP, or in the induction of 
NF-kB in case of NOD proteins. The RLRs (RIG-I and MDA5) activate NF-kB, but also induce type 
I IFNs production via IRF3 and IRF7. 
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1.3  T cells stimulation by Dendritic cells 
1.3.1 T cells immunity 
 Several unique properties contribute to the prominent role of DCs in the initiation and 
modulation of adaptive immune responses: the great efficiency in antigen uptake and processing, the 
unique capacity of sensing and integrating different environmental signals and the ability to migrate 
and to localize in T cells rich areas of secondary lymphoid organs. Is in this definite area of lymph 
nodes that antigen specific immune responses initiate by engagement of the T cell receptor (TCR) 
with the cognate peptide-MHC complex displayed by the DCs. TCR triggering determine the 
antigen-specificity of the response and represents the fist of the three signals delivered by DCs that 
dictates the fate of naïve T cells. The second signal is referred to as T cell co-stimulation and is 
mediated by the engagement of both positive (CD28) and negative (CTLA-4 and PD-1) co-
stimulating receptors on T cells by DCs. The fine balance between these positive and negative 
signals controls the initiation of protective immunity. If the DC is not fully activated, due to the lack 
of inflammatory stimuli, negative signals prevail leading to T cell inactivation by anergy or deletion 
and the induction of a state of tolerance (83). Finally, T cells sense and integrate signals, mediated 
by different cytokines and chemokines (referred to as signals 3) that are produced by DCs and whose 
nature strictly depends on the conditions under which DCs are primed. The set of secreted cytokines 
determine the extent of T cells proliferation, the survival and the ability to develop effector functions 
and specifically the differentiation into effector cytotoxic T cells or the acquisition of a TH1, TH2, 
TH17 of T regulatory phenotype in case of CD8+ and CD4+ T lymphocytes respectively. 
 
1.3.2 Dendritic cell maturation and T cell priming 
 Several studies initiated almost a decade ago, have provided the direct evidence that DCs 
play a crucial role not only in the induction of adaptive immunity, but also in the maintenance of 
peripheral tolerance to self and nonpathogenic environmental antigens. Pioneering work by Kurts et 
al. initially showed how the constitutive cross-presentation of ovalbumin, expressed as a transgene 
in several organs (pancreatic islets, kidney tubular cells, thymus and testis) of RIP-mOVA mice by a 
bone-marrow derived APCs, induced the proliferation of adoptively transferred Ag specific CD8+ T 
cells (OT-I) in the lymph nodes draining these organs. However, this initial OT-I activation was 
followed by the progressive removal of the autoreactive T cells via a deletional mechanism that 
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ultimately led to an immune tolerant state (84). Further studies by Steinman group implicated DCs 
as the APCs responsible for tolerance induction. They showed that in a steady state condition (i.e. 
absence of inflammation), direct targeting of DCs in situ through DEC205 induced the efficient 
presentation of the peptide HEL (fused to anti-DEC antibody) on MHC class II molecules and the 
extensive proliferation of adoptively transferred HEL-specific CD4+ T cells. However, the activated 
T cell were eventually deleted unless an additional DCs activation signal, such as CD40 ligation, 
was provided (85). A second study by the same group extended these findings on Ag specific CD8+ 
T cells. Targeting DCs via an anti-DEC-205 Ab coupled to OVA induced the efficient cross-
presentation of the Ag and the extensive proliferation of adoptively transferred OT-I cells. However, 
by 10-12 days, the stimulated T cells underwent a deletional mechanism, being entirely absent from 
lymph nodes, spleen and blood and were unresponsive upon rechallange with OVA Ag, thus proving 
the induction of peripheral tolerance. Similarly to the previous study, the co-administration of an 
agonistic anti-CD40 antibody as an adjuvant, activated DCs in situ and produced a strong CTLs 
response and memory (86). 
The finding that cross-presentation of different forms of Ags, either soluble proteins (85, 86) or 
dying cells (87) by steady state DCs is an essential mechanism to guarantee tolerance to self, was 
further extended to the classical pathway of MHC class I presentation by works performed in van 
den Broek laboratory. Probst et al. used a transgenic mouse model (DIETER) that allows the 
controlled expression and presentation of lymphocytic choriomeningitis virus (LCMV)-derived CTL 
epitopes exclusively by DCs. They observed that activated DCs (by systemic administration of anti-
CD40 Ab), efficiently primed naïve endogenous CTL to proliferate and to differentiate into 
protective effectors, whereas resting DCs induced Ag specific tolerance, that could not be broken by 
a subsequent infection with LCMV (88).  
Collectively, all these data demonstrate that DCs maturation state is the critical switch that provides 
signals for effector T cell development and memory, diverting T cells from anergy or deletion to 










 Several properties of mature DCs could account for their capacity to efficiently prime T 
lymphocytes and to induce their differentiation into long-lived functional memory. Among these, the 
increased expression of co-stimulatory, MHC and adhesion molecules which are crucial in 
controlling the stability and the duration of the DC-T cell contact (90) so that the duration of the 
TCR signaling may influence the functional outcome of T cells activation (91). In addition, mature 
DCs secrete immune enhancing cytokines like IL-12 and type I/type II IFNs that favor the 
differentiation of T lymphocytes into effector cells and T cells survival. On the contrary, immature 
DCs induce peripheral T cell tolerance through combined mechanisms of antigen specific T cells 
deletion and functional inactivation or by generation of regulatory T cells. However, the in vivo 
relative contribution of these mechanisms remains still elusive and may largely depend on the 
specific experimental setting and model analyzed. For instance, delivery of antigens to steady state 
DCs via DEC205 leads to T cells tolerance by both deletional mechanisms (85, 86) and induction of 
CD4+/CD25+ regulatory T cells (92). Alternatively, presentation of cellular antigens expressed by 
resting DCs results in the depletion of antigen specific T cells upon engagement of the T cells co-
inhibitory molecules PD-1 and CTLA-4 (83). Finally, a population of CD103+ DCs found in the 
mesenteric LNs is able to promote the conversion of naïve T cells into Foxp3+ T reg cells upon oral 
administration of the antigen, in a mechanism dependent on TGFβ and retinoic acid (93). 
 
1.3.3 Dendritic cell “licensing” by CD4+ T cells 
 Dendritic cells play a prominent role in the generation of CTL responses not merely by 
presenting antigens, but in supplying critical co-stimulatory and differentiation-inducing mediators 
that guide the development of lymphocyte responses. Experimental evidences from the late of 1990s 
led to a model of DCs licensing, in which antigen-specific CD4+ T cells interacted with DCs via 
CD40/CD40L interactions and conferred upon DCs the ability to prime CTL responses (94, 95). 
Whether such CD4+ T cells help is essential for the induction of primary CTL responses or in the 
generation of functional memory CD8+ T cells it is still an open issue and a matter of intense study. 
The generation of a primary CD8+ T cells response has been shown to be independent from the 
cognate T cells help in various experimental settings of acute infection such as Listeria 
monocytogenes and lymphocytic choriomeningitis virus (96-98). However, the situation changes 
during chronic infections, HSV infection, or in noninflammatory conditions where the antigen 
specific CD8+ T cell response is greatly impaired in the absence of CD4+ T cells (99, 100). A 
possible explanation is that the CD4+ T dependency of primary CTL responses is inversely 
correlated with the level of inflammation and other danger signals present during initial priming. In 
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this context, the recognition of PAMPs by TLRs and other PRRs may lead to a DCs activation status 
that allows to bypass the need for CD4+ T cells help (95). 
A second critical issue regards the requirement of CD4+ T cell help in generating functional CD8+ T 
cell memory. In this setting, many studies have clearly demonstrated that even if the primary CTL 
response to pathogens like Listeria monocytogenes and lymphocytic choriomeningitis virus fully 
develops in a TH independent manner, the resulting memory CD8+ T cell population is poorly 
functional and unable to undergo a second round of clonal expansion following re-encounter with 
the antigen (96-98). The general accepted view is that CD4+ T cell help makes the initial CD8+ 
response bigger and programs the differentiation of responding CD8+ T cells into long lived, 
protective memory. However, exactly what CD4+ T cell provide to maintain CD8+ T cell memory 
remains a mystery (95). Janssen and colleagues showed that the un-helped CD8+ T cells undergo 
death, which is mediated by TNF-related apoptosis-inducing ligand (TRAIL) upon antigen 
restimulation (101). The regulation of Trail expression by CTLs may thus be one of the mechanisms 
by which CD4+ T cells influence the generation of CD8+ T cell memory. 
 
 A critical point is whether different stimulatory signals can bypass the requirement for CD4+ 
T cell help in the induction of fully efficient memory CTLs. In a recent study, Hervas-Stubbs et al. 
evaluated whether signals generated by TLR engagement may be sufficient to cross-prime 
effector/memory CTLs independently of CD4+ T cells help. This was achieved by immunizing mice 
with synthetic microsphere covalently linked to the OVA class I peptide together with different TRL 
ligands. This work showed that the requirement for T-cell help to trigger effector CTLs can be 
bypassed by TLR3-L (poly(I:C)) and TLR9-L (CpG mixed to a lipid formulation), but not with 
TLR2/4/7-L, although they induced DCs maturation and IL-12 secretion. The production of type I 
IFNs was necessary to induce a full CTL response but not sufficient alone, since it required the 
concert action of other proinflammatory cytokines. Finally, the “helpless” CTLs induced by TRL3-L 
differentiated into functional memory CTLs able to proliferate upon secondary immunization, thus 
proving that signals derived from TLR triggering can bypass the requirement of CD4+ T cells help 
(102). Further studies will be required to assess whether the engagement of other activating receptors 





1.3.4 Dendritic cells control of T-cell polarization 
 Dendritic cells have a central role in the orchestration of various forms of immunity and 
tolerance. They can modify and adapt the T-cell response to the type of invading pathogen by 
developing into functional DC phenotypes that initiate either TH1, TH2, TH17 or T regulatory 
responses. It is becoming increasingly clear that the way in which DCs bias the development of TH 
cell subsets is related to the engagement of specific receptors that are involved in DC maturation. 
The integration of the signals triggered by multiple PRRs upon antigen encounter and the factors 
produced in the surrounding tissues by infected cells, lead to the polarized maturation of DCs and 
the subsequent production of specific molecules, primarily cytokines, that promote TH1, TH2, TH17 
or regulatory T cell development. 
In general, TH development is characterized by the presence of reiterative feedback mechanisms that 
propagate the early lineage decision once initiated (103), i.e. the cytokines produced by a given 
helper T cell subset often serve as potent inducers of the differentiation of that subset, as well as 
negative regulators of the other subsets. Cytokines regulate TH differentiation by repressing or 
inducing the transcription of genes encoding for key transcription factors which in turn, activate 
specific cytokines receptors genes and thus define the growth factor preference of each mature 
helper T cell lineage (104). If the identification of the key transcription factors that regulate the 
development of specific TH subsets has shed light on the signaling pathways that sustain TH cells 
differentiation once initiated, on the other side, the identity of the DCs PRRs whose engagement 
drive the polarized maturation of DCs is far from being complete. 
 TH1 cells polarization evolved to enhance clearance of a broad spectrum of intracellular 
bacteria, viruses and some parasites. Engagement TLR3, 4, 7 and 9 on DCs by these pathogens 
results in the production of both types of IFNs and IL-12, which play a crucial role in inducing TH1 
cells differentiation and in the cell proliferation and survival of committed TH1 cells respectively. 
TH1 differentiation is coupled to the sequential action of IFNγ and IL-12 through a signalling 
pathway that involves STAT1 and the transcription factor T-bet (103), which represent the master 
regulator of TH1 cells (105). 
 Marked TH2 responses are induced by infection with parasistic helminths and various 
allergens. Although phosphorylcholine-containing glycoproteins and polylactosamine sugars from 
different parasites have been shown to induce the maturation of DCs that polarize a TH2 type of 
response, the PRRs responsible for this effect still remain to be established. The key cytokine 
involved in TH2 differentiation is IL-4 that initiate a signaling pathway via STAT6 and leads to the 
upregulation of the transcription factor GATA-3. This master regulator of TH2 differentiation 
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induces the transcription of Il4, Il5 and Il13 genes while suppressing the factors critical to TH1 
pathway. 
 TH17 cells are a third class of effector CD4+ T lymphocytes that has been implicated in 
numerous autoimmune and inflammatory conditions including arthritis, multiple sclerosis, psoriasis 
and inflammatory bowel diseases and are characterized by production of a distinct profile of effector 
cytokines, including IL-17 and IL-6 (104). They probably have evolved to enhance the host 
clearance of a range of pathogens distinct from those targeted by TH1 and TH2 (103). Indeed, IL-17 
has been linked to resistance to infection by extracellular bacteria such as Klebsiella pneumoniae as 
well as by fungi such as Candida albicans (106). Although the PRRs able to induce a DCs 
phenotype that initiate a TH17 response are largely unknown, a recent work by Reis e Sousa group 
showed how the dectin-1-Syk-CARD9 signaling pathway promotes DCs maturation and the 
secretion of proinflammatory cytokines such as IL-6, IL-2, TNF and IL-23 that strongly bias TH 
differentiation to TH17 fate. Indeed, large amount of IL-17 were produced by CD4+ spleen cells from 
mice infected with C. albicans thus linking the induction of TH17 responses to fungal infection. The 
authors also showed that TH17 differentiation is dependent on the presence of T regulatory cells and 
requires TGFβ (19). These data are consistent with reports suggesting that TGFβ and IL-6 act in the 
first step of TH17 development, by activating the key transcription factor RORγt, and that IL-23 acts 
secondarily probably to expand the committed TH17 effectors or maintain their function (104). 
 Finally, exposure of DCs to cytokines like IL-10 and TGFβ can induce the differentiation of 
CD4+ T cells into a distinct regulatory subsets characterized by the ability to suppress adaptive T cell 
responses and prevent autoimmunity. Regulatory T cells that develop from naïve CD4+ T cell 
precursor in the periphery are called adaptive Treg and differ from the naturally occurring regulatory 
T cells that develop intrathymically. At least two types of adaptive Treg have been described. Treg1 
cells develop under the control of IL-10-conditioned DCs, do not express the transcription factor 
Foxp3 and are marked by the production of high amount of IL-10. Treg2 instead, are induced from 
naive precursors under the influence of TGFβ, express Foxp3+ and have suppressive activities 
indistinguishable from naturally occurring Treg (104). Indeed, proinflammatory cytokines such as 
IL-6 and IL-1 that are released by TLR-matured DCs, are able to subvert Treg suppression, but at the 
same time they also reverse the Treg anergic state thus permitting their proliferation while retaining 
the suppressive functions once proinflammatory cytokines production ceases (103). Moreover, many 
pathogens such as Mycobacteria species which bind to DC-SIGN, Schistosoma mansoni and 
Yersinia species to TLR2 or Plasmodium falciparum infected erythrocytes to CD36 and CD52, have 
been described to prime DCs to support the development of regulatory T cells as a mechanism of 



































Figure IV. Dendritic cells effector function. Immature DCs can give rise to 
multiple types of “effector” DC that instruct distinct T-cell fates, including 
immunity, tolerance and immune deviation. Maturation refers to the changes that 
accompany immature DC transition to a given effector state in response to 
environmental signals of exogenous (microbial) or endogenous (cytokines, 
hormones, dying cells) origin. The quality of these signals determines the choice 
of effector DC, although ontogeny can also have a role, predisposing certain DC 
subtypes towards particular effector states. Some maturation signals can promote 
the generation of tolerogenic DCs. This does not negate the possibility that some 
immature DCs have an intrinsic tolerogenic function.  
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1.4 Dendritic cells subsets and T cells priming 
1.4.1 Dendritic cells subsets 
 The phenotypic and functional analyses of the DCs found in the thymus, spleen and lymph 
nodes have revealed a considerable heterogeneity among the DCs population, such that different 
DCs subsets have emerged and described as following a life cycle that differed from the original 
“Langerhans cell paradigm” (3). Although all DCs are capable of antigen uptake, processing and 
presentation to naïve T cells, the DCs subtypes differ in hematopoietic origin, location, migratory 
pathways, immunological functions and dependence on infection or inflammatory stimuli for their 
generation (7). 
 A first criteria to classify DCs is to distinguish among conventional DCs (cDCs) that have a 
dendritic form and exhibit DCs functions in steady state, from precursors of DCs (pre-DCs), that 
require further development to acquire DCs phenotype and full DCs function. Although the 
development of some pre-DCs can occur in steady state, in many cases the further development of 
pre-DCs requires a microbial or inflammatory stimulus (7). An example of pre-DCs are the 
plasmacytoid DCs that circulate through the blood and lymphoid tissues and only acquire the typical 
DCs morphology upon activation. Also monocytes can serve as source of pre-DCs and differentiate 
into functional DCs upon infection or inflammatory conditions (108, 109). 
 Among conventional DCs, two main categories can be distinguished based on the path they 
follow to access the lymphoid organs: migratory DCs and lymphoid-tissue resident DCs. Migratory 
DCs comprise epidermal Langerhans cells and interstitial or dermal DCs. The two subsets can be 
readily distinguished by the selective expression of the C-type lectin langerin on the surface of 
epidermal LCs and by LC-specific intracellular organelles known as Birbeck granules (110). 
Migratory DCs follow a life cycle described by the Langerhans cell paradigm serving as antigen 
sampling sentinels in the peripheral tissues and trafficking to the lymph nodes in response to danger 
signals. Migratory DCs display a mature phenotype in LNs also in steady state conditions, indicating 
that their migration and maturation proceed constitutively and independently of pathogens and are 
probably triggered by inflammatory compounds that are constitutively released by peripheral tissues 
(3). 
Lymphoid-tissue resident DCs or blood-derived DCs constitute half of the lymph node DCs (the 
second half being migratory DCs) and all the DCs found in the spleen and thymus (6). They can be 
further subdivided into three subsets depending on the expression of CD4 and CD8 markers: 
CD4+CD8-, CD4-CD8+ and CD4-CD8- cells. Resident DCs do not conform to the Langerhans cells 
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paradigm, since they develop from bone marrow precursors directly in secondary lymphoid organs 
without previously trafficking through peripheral tissues. In contrast to migratory DCs, blood-
derived DCs maintain an immature phenotype in steady state, but can be induced to mature by 
inoculation of inflammatory stimuli. Thus the function of the immature lymphoid organ DCs may be 
to promote tolerance in steady state while maintaining their capacity to respond to infections 
reaching those organs (6). 
 
 
Table I. Mouse dendritic-cell subsets 
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1.4.2 Dendritic cells subset and antigen-presenting functions 
 Since the initial characterization of different DCs population less than a decade ago, a great 
effort has been spent trying to elucidate the role of various DC subsets in the initiation of adaptive 
immune responses or in the maintenance of a tolerogenic state under normal circumstances. A 
scenario where the coordinate action of the different DCs subtypes, each with a specific function, 
operates to mount effective responses against specific pathogens or to prevent such responses in the 
absence of danger can be envisaged. 
The possibility to isolate highly pure populations of DCs from different lymphoid organs taking 
advantage of specific lineage markers and the generation of transgenic mice that allows the tracking 
(111) or the conditional ablation of specific DCs types in vivo (57) have allowed to investigate the 
relative efficiency of DCs in priming T cell responses and their differential contribution to in vivo 
immune responses. 
Although all DCs types express high levels of MHC class I and MHC class II molecules, especially 
when mature, and are able to generate peptide-MHC complexes, an increasing amount of data is 
indicating a different ability of the various DCs subset to incorporate peptides, derived from a given 
antigen, into their presentation pathway and thus a different capacity to activate CD4+ or CD8+ T 
lymphocytes. 
 
 Plasmacytoid DCs (pDCs) are a principal subset of DCs in both human and mouse with a 
unique ability to sense and respond to viral infections mainly by secreting large amounts of type I 
IFNs. Differently from conventional DCs, pDCs constitutively express the IFN regulatory factor 7 
(IRF-7) that allows the rapid secretion of vast amount of IFN-α in a signaling pathway initiated by 
TLR7 and TLR9 engagement. Due to their poor phagocytic activity and thus inefficiency to present 
antigens (112), pDCs were generally considered to have a role in boosting the ability of conventional 
DCs to mature and stimulate T cells in viral infections, rather than playing a direct role in antigen 
presentation. However, recent findings by Sapoznikov et al indicate that pDCs are indeed able to 
initiate productive CD4+ T cell responses in lymph nodes upon antigen challenge. Taking advantage 
of mice conditionally depleted of CD11chi cDCs but retaining a normal pool of pDCs, the authors 
demonstrate how the ability of this specific subset to trigger antigen specific CD4+ T cell responses 
is organ dependent, being limited to lymph nodes and absent in spleen. The unique priming of CD4+, 
but not CD8+, T cell responses by pDCs could result from exclusive presentation of exogenous 
antigen on MHC class II, but not MHC class I molecules and would predict that pathogens that 
specifically activate pDCs will elicit exclusively humoral but not citotoxic immunity (113). 
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 Migratory DCs present in the epidermis (Langerhans cells) and in the dermis (interstitial 
DCs) are characterized by the expression of many PRRs and endocytic receptors and are able to 
efficiently mediate the uptake of macromolecules and a broad range of microorganisms (114). 
Residing in most peripheral tissues at site of interface with the environment, migratory DCs 
constitutively take up antigens and traffic to lymph nodes where they interact with both CD4+ and 
CD8+ T lymphocytes. Indeed, cutaneous DCs express upon activation high levels of MHC class I 
and class II molecules and are able to efficiently prime both T helper and cytotoxic T lymphocytes. 
Conversely, their ability to cross-present soluble or cell-associated antigens is less defined. In a 
mouse model of autoimmunity, where the OVA class I peptide is expressed under the control of the 
human keratin 14 promoter (K14-OVAp mice), Langerhans cells have been demonstrated to cross-
present this highly expressed antigen in the skin draining LNs and to induce the expansion of antigen 
specific cytotoxic T cells endowed with effector functions (115). A recent study by Romani group 
showed that Langerhans cells in epidermal skin explants were able to cross-present soluble and cell-
associated antigens in a TAP-dependent manner. Interestingly, the in vitro comparison of the relative 
efficiency of Langerhans cells and CD8α+ resident DCs to present an exogenous antigen on MHC 
class II or cross-present it on MHC class I molecule was different, with CD8α+ spleen cells being 
more potent in inducing CD8+ T cells and Langerhans cells better in stimulating CD4+ T cells (116). 
Whether migratory DCs are the main DCs subset involved in the presentation of peripheral-tissue 
antigens or antigens derived from pathogens that infect the skin, lungs or gut, to both CD4+ and 
CD8+ T cells is still a matter of controversy. Although migratory DCs have an essential role in 
carrying peripheral antigens to the draining lymph nodes, recent studies using various models of 
viral infection have highlighted the dominance of the non-migrating, lymph node-resident CD8α+ 
DCs subset in priming CTL responses thus implicating the transfer of peripheral antigens from 
migratory to resident DCs upon entry in the T cell areas of the lymph nodes (59, 61, 117). 
Villadangos et al propose a model where the relative contribution of the two subsets to the 
presentation of peripheral antigens depends on the pathogen capacity to infect DCs or impair their 
antigen presenting functions and on the number of antigen-carrying migratory DCs that reach the 
lymph node (3). 
 
 The DCs that reside in the lymph nodes and in the spleen are ideally located to monitor the 
blood for the presence of infectious agents that spread through circulation and thus should play a 
major role in the induction of immune response against blood-borne pathogens. The fact that 
intravenous inoculation of inflammatory compounds such as LPS or CpG induce the activation of 
conventional DCs, their migration to the T cell areas of spleen and LNs, the acquisition of a mature 
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phenotype and the secretion of large amount of IL-12, support the hypothesis that cDCs indeed play 
a major role in immunosurveillance. On the other hand, if peripheral tolerance is mediated by 
immature DCs, the large number of blood derived DCs contained in the steady state in the lymphoid 
organs would provide a strong tolerogenic environment for naïve T cells (118). Due to their crucial 
role in the control of immunity, the definition of the in vivo relevance of the various subsets of 
lymphoid organ resident DCs in terms of antigen presenting functions has been subject of intense 
study. 
Both in vitro and in vivo analysis of the capacity of blood-derived DCs subsets to present exogenous 
antigens on MHC class II or cross-present them on MHC class I have revealed a functional 
dichotomy between the CD8α+ and CD8α- (comprising both CD4+ and double negative DCs) 
subsets of resident DCs. Specifically, it emerges that the CD8α+ DCs are by far the most efficient at 
cross-presenting cellular (119, 120), soluble (121, 122) or latex bead-associated antigens (122). 
Indeed, the ability of CD8α+ DCs to cross-present cellular associated antigens is attributable to their 
selective capacity to endocytose dying cells in culture and in vivo (120, 123). 
Furhtermore, CD8α+ DCs have also been identified as the major subset involved in the MHC class I 
presentation of antigens from viruses (HSV1, influenza and vaccinia virus) and cytosolic bacterium 
L. monocytogenes (61, 124). By contrast, CD8α- DCs seem to be more efficient than CD8α+ DCs at 
presenting exogenous antigens on MHC class II molecules, especially in the case of phagocytosed 
antigens (i.e antigens associated to latex beads) (122) and soluble antigens, although less evident 
(120-122). 
The CD8α+ and CD8α- subsets of DCs differentially express multiple putative antigen receptors 
belonging to the C-type lectin family. The DEC-205 and mannose receptors are primarily expressed 
by the CD8α+ DCs (125, 126), whereas dectin-1, DCIR2, FIRE and CIRE are specific for the CD8α- 
DCs (127-129). Targeting of soluble antigens coupled to antibodies against these various receptors 
has shed light on the in vivo role of the two DCs subtypes and allowed to characterize the type of 
immune response (humoral vs cytotoxic) preferentially triggered by these DCs subsets. Collectively, 
these studies highlight the greatest efficiency of CD8α+ DCs to activate CTLs and the preferential 
induction of CD4+T cells and humoral responses by the CD8α- DCs (127-129). 
As suggested by Dudziak et al, a possible explanation of this dichotomy is the differential expression 
of various components of the MHC class I and MHC class II machinery by the CD8α+ and CD8α- 
subsets respectively (127). Alternatively, the MHC class I and class II pathways are fully operational 
in both subsets, but in addition, the CD8α+ DCs possess a specialized machinery for cross-
presentation which is largely absent in the CD8α- subtype (3). A recent work by Burgdorf et al 
demonstrate how the CD8α+ DCs are able to preferentially deliver exogenous antigens to either the 
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MHC class I or class II pathways depending on the mechanism of antigen uptake. Specifically, 
mannose receptor mediated endocytosis results in cross-presentation of ovalbumin, whereas 
pinocytosis conveys OVA to lysosomes for MHC class II-restricted presentation (126). It is thus 
plausible that cross-presentation requires the delivery of antigens to a specialized compartment that 
is found only in the CD8α+ subset of DCs (3). 
 
The better understanding of the in vivo functions and of the interplay among DCs type will indeed 
provide new possible strategies to potentiate the immune response against poorly immunogenic 
pathogens, to shift the type of immune response according to the infectious agents and finally to 











Table II. Uptake, MHC class I and MHC class II presentation of several model antigens by CD8+
and CD8- dendritic cells. 
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1.5 Dendritic cells based cancer vaccines 
 Due to their central role in the orchestration of all elements of the immune system, dendritic 
cells have emerged in the past few decades as a fundamental target and tool for cancer 
immunotherapy. 
Current approaches are based on the immunization of cancer patients with autologous, patient-
derived DCs loaded with tumor antigens ex vivo. Indeed, numerous studies in mice have shown that 
DCs loaded with tumor antigens can induce therapeutical and protective antitumor immunity (130). 
Furthermore, the immunogenicity of antigens delivered by DCs has also been shown in patients with 
cancer or chronic infections, thus providing the proof of principle that using DCs as vaccines can 
work (131). 
In the recent years, strategies have been developed to generate large numbers of clinical-grade DCs 
from various types of progenitors cells. Moreover, several protocols have been designed to load 
different formulations of antigens on DCs and to provide the cells with the activation stimuli 
necessary to optimize their antigen presenting potential and T cells stimulatory capacities. 
Despite the limited rate of objective tumor regressions that has been observed in clinical studies so 
far, the increasing knowledge of DCs functions in vivo and the discovery of the factors that 
contribute to the tumor-induced immunosuppression will indeed provide the rational for new 
combined DCs vaccination protocols with an enhanced clinical efficacy. 
 
1.5.1 Ex vivo generation of immunocompetent DCs 
 A first critical parameter for the production of DC vaccines is the number of DCs that need to 
be isolated/generated, keeping in mind that cancer patients may present alterations in the number, 
phenotype and functionality of DCs isolated from peripheral blood or generated from monocytes 
precursors (132). 
DCs (both myeloid-derived and plasmacytoid) can be isolated directly ex vivo from the blood of 
patients, either through positive selection using DCs-specific markers or by depletion of 
contaminating cells or by a combination of both. Despite the fact that Flt3-L (fms-related tyrosine 
kinase 3 ligand) can be used to mobilize blood DC, yields are generally too low to obtain sufficient 
numbers of DCs for vaccination. 
Human DCs can be generated in culture from CD34+ hematopoietic progenitors, which can be 
isolated from blood or bone marrow by positive selection and differentiated into DCs by addition of 
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different cytokine mixtures (e.g. GM-CSF and TNFα or GM-CSF and IL4/IL13) for 2 weeks. 
Purities are variable and rather low, with the contaminating cells being mainly granulocytes (132). 
The most commonly used cells type for DCs generation is the peripheral blood monocytes that can 
be differentiated into immature “myeloid-type” DC by a 5-7 day culture in the presence of GM-CSF 
and IL4 or GM-CSF/IL13 and type I IFNs (132). Alternatively, several rapid, two-days “fast-DC” 
protocols have been developed that generate DCs able to stimulate T cells responses in vitro as 
effectively as DCs generated by standard protocols (133). 
 For cancer vaccination, the goal is to generate ex vivo a population of antigen-loaded DCs 
that stimulate robust and long-lasting CD4+ and CD8+ T cell responses in patients with cancer. This 
imply the setting up of protocols that reproduce ex vivo the development of immunocompetent DCs 
and the process of DCs activation. 
DCs need to be generated in vitro such that they undergo optimal maturation (i.e. expression of co-
stimulatory molecules, lymph node migratory capacity and proper cytokine secretion) and become 
responsive to licencing stimuli when they reach the lymph node and encounter cognate T cells. The 
most widely used maturation protocol for human monocytes-derived DCs consist of a cytokines 
cocktail including TNF, IL1β, IL6 and PGE2, also known as monocyte-conditioned medium (MCM) 
(134). However, a recent phase III clinical trial failed to demonstrate that vaccination with peptide 
loaded, MCM-matured DCs was more efficient than standard decarbazine chemotherapy in stage IV 
melanoma patients (135). Extensive controversy exists about which stimulus might be optimal. A 
recent work by Sporri and Reis e Sousa has shown that optimal activation of DCs requires TLRs 
signaling (136) in combination to inflammatory cytokines. A promising maturation protocol that 
includes TNF, IL1β, PolyI:C, IFNα and IFNγ, induced the differentiation of DCs that retained 
lymph node migratory capacity, responsiveness to IL12 and were able to generate potent CTL 
responses (137). An alternative is to provide DCs with a maturation stimulus directly in situ by 
injecting immature DCs into sites that have been pre-treated with adjuvants (TLRs ligand) to induce 
local inflammatory reaction. Clinical trials are ongoing to assess the therapeutic efficacy of this 





























1.5.2 Loading dendritic cells with tumor antigens 
 The ideal target for cancer immunotherapy would be a tumor associated antigen (TAA) 
which is exclusively expressed in tumor cells and not in normal tissues, to avoid the potential 
induction of autoimmunity. In addition to the type of antigen used, the modality of antigen loading 
on DCs will have a great impact on the its ability to access the MHC class I and MHC class II 
presentation pathways and thereby will influence the type of T cells response. Antigens can be added 
exogenously in the form of short peptides, whole proteins, tumor lysates or apoptotic debris or 
complexed with antibody. Alternatively, DCs can be engineered to synthesize it endogenously by 
transfection with mRNA encoding the antigen. 
The most commonly used protocol for loading Ags onto DCs is pulsing with short synthetic peptides 
corresponding to the MHC class I and MHC class II epitopes of TAAs. Apart the obvious 
advantages, important drawbacks are the need to determine the MHC haplotype of the patient, the 
paucity of known tumor specific peptides and the limited persistence of the peptide-MHC complex 
on the surface of the DCs. 
Figure V. DC-based vaccines 
using ex vivo loaded DCs to 
induce immunity. Most of the
DC-based vaccines currently 
explored in clinical trials consist 
of mature antigen-loaded 
autologous DCs that are 
administered to patients with the 
intention of inducing antigen –
specific T- and B-cell responses. 
The DCs used for these studies 
are derived from monocytes of 
CD34+ precursors that are 
isolated from patients blood by 
cytapheresis. These cells are 
cultured in the presence of 
various cytokine mixture to 
produce immature DCs, and 
loaded with antigen either 




TAAs like carcinoembryonic antigen (CEA), prostate specific antigen (PSA) or antigens expressed 
in virtually every type of cancer (“universal” antigens) such as survivin and telomerase reverse 
transcriptase (TERT) can be loaded on DCs as whole proteins, allowing the derived peptides to be 
channelled into both MHC class I and class II presentation pathways independently of the patient 
MHC haplotype. However, a major limit of this methodology is the access to clinical grade reagents. 
Methods that take advantage of the complete protein content of the tumor cell and thus broaden the 
induced immune response, have been developed, including loading the DCs with tumor lysate or 
tumor-derived exosomes, engulfment of apoptotic/necrotic cells by DCs and fusion of DCs with 
tumor cells. However, the need to isolate a high number of tumor cells, the complex modality of 
antigen preparation and the safety concerns, represent the major drawback of these vaccination 
strategies. 
A genetic approach based on the electroporation of DCs with mRNAs that encode for tumor derived 
antigens or mRNA amplified from whole tumors associates the ease of isolating the genetic material 
to the opportunity to induce a broad patient specific immune response against both known and 
unknown TAAs. One main drawback is that antigen is mainly channelled to the MHC class I 
presentation pathway, thus limiting the generation of effective CD4+ T cells responses. 
Advancing knowledge on the intracellular routing of antigens allows for the rational design of 
effective vaccines by manipulating the antigens to induce optimal T-cells priming. Antigens can be 
engineered and fused to targeting signals for different intracellular compartments, so that 
rechannelling of a cytoplasmic antigen into the MHC class II presentation pathway can be achieved 
by fusing it to the lysosomal targeting signal (138). Alternatively, fusogenic peptides that are based 
on the N-terminal sequence of the influenza virus haemagglutinin protein can be applied to enhance 
cytoplasmic delivery of proteins thus possibly stimulating antigen cross-presentation (139). 
Besides the form of the antigen, other important factors to be considered are the amount of antigen 
loaded on the DCs, the efficiency of loading, the length of time the antigen will persist and be 










1.5.3 Clinical trials with DC-based vaccines 
 A substantial number of clinical trials on different cancers, using dendritic cells has been 
carried out over the last decade. Results are difficult to compare due to the variability in the type and 
activation state of the DCs used, the antigen loading methods, the use of different 
immunomonitoring methods and non-objective clinical criteria and the overall study design (132). In 
most of the trials, a fraction of patients exhibited immune responses against the vaccinating antigen, 
but durable clinical responses were exceedingly rare. However, these studies have generally be 
pursued in patients with late stage cancer with poor prognosis and the patients probably suffer from 
immunosuppression as a results of a large tumor burden and prior radiation therapy or chemotherapy 
(140). So, at the moment the single observation that can be made is that DC vaccination is safe and 
well tolerated, as no or mild adverse effects have been reported only in a small number of patients 
(137). 
So far, the published studies highlight some critical aspects that have to be considered for the future 
design of DCs-based vaccination strategies. Among these, the necessity to use properly activated 
DCs by the combination of multiple maturation stimuli and the use of antigen loading approaches 
that favor the generation of both peptide-MHC class I and peptide-MHC class II complexes. 
 Another variable possibly influencing the effectiveness of DC vaccination is the route of vaccine 
administration. Preliminary results from clinical trials indicate that intravenous injection primarily 
induces humoral immune responses, whereas intradermal and intranodal injection mediate the 
induction of TH1 immunity (141). Conversely, subcutaneously injected DCs fail to migrate to the 
lymph node (142). This is probably due to the fact that most of the DCs sense other DCs in the 
vaccination mixture and fail to contact the microenviroment. Therefore, administration of DCs by 
multineedle devices may results in better dispersal, contact with the microenviroment and thus 
increased DCs migration (137). 
Finally, the boosting frequency may affect the efficacy of DC vaccination. Current protocols vary 
among weekly, biweekly and monthly intervals. However, recent mouse studies suggest that more 







1.5.4 Future perspectives: in vivo dendritic cell targeting 
 The optimization of antigens delivery to dendritic cells is a crucial factor to improve the 
efficiency of current DCs-based vaccination protocols. 
The discovery that the uptake of extracellular material through receptor mediated endocytosis greatly 
increases the efficiency of antigen capture, allowing DCs to present antigens found at picomolar and 
nanomolar concentration, led to the hypothesis that targeted delivery of antigens to dendritic cell 
surface molecules might increase T cell mediated immune responses. Indeed, uptake of immune 
complexes through Fcγ receptors results in DCs maturation and antigen cross-presentation to T cells 
(15). Moreover, immunization of mice with tumor antigen in the form of immune complexes was 
shown to induce antigen specific T cells responses and tumor protection (143). 
The identification of receptors that are more or less specifically expressed by DCs and the 
availability of antibodies that are directed against these receptors or the knowledge of their natural 
ligands, led to the development of vaccination strategies based on targeting antigens to DCs in vivo. 
The major advantage is the relative easiness of large-scale production of GMP-grade vaccines and 
the opportunity to target natural DCs subsets leading to the activation of the cells within their natural 
environment. 
So far, these targeting studies have revealed that the efficacy of in vivo DC vaccination depends on 
various factors including the expression pattern and biological properties of the specific receptor and 
the maturation or activation status of the DCs (140). 
 Initial studies in mouse models, identified the C-type lectin family receptor DEC205 as the 
ideal candidate to target DCs in vivo (85, 86). DEC205 was found to be highly expressed by DCs 
within the T cells area of lymphoid tissues and subcutaneous injection of the anti-DEC205 mAb 
NLDC145 was shown to specifically stain CD11c+MHCII+ DCs in lymphoid tissues (85). Further 
studies then demonstrated that in vivo delivery of various antigens coupled to the anti-DEC205 Ab 
greatly increased the efficiency of antigen presentation on both MHC class I and class II molecules 
(85, 86, 144), so that targeting of activated DCs via DEC205 resulted in improved T cells 
vaccination and led to the induction of an anti-tumoral response (145, 146). 
Apart DEC205, various members of the CLRs family such as CIRE and FIRE, dectin-1 and DCIR-2 
were shown to increase the efficiency of antigen presentation and induce Ab response in mouse 
models of DCs targeting (127-129). Of note, the type of response was qualitatively different from 
that triggered by DEC205, providing evidence that in vivo targeting of various receptors on different 
DCs subsets has different immunological outcomes both in terms of type of T cells response elicited 
and the requirement of additional adjuvant stimulation. 
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Other studies performed in mice and focusing on different classes of endocytic receptors such as 
scavenger receptors (Lox-1) (27), TNF-receptor superfamily (CD40) (147) and integrins (CD11c) 
(148) further proved that antibody mediated targeting of APCs is a promising strategy to elicit Ag-
specific immune responses and induce protection in various tumor models. Moreover, not only the 
antibodies directed against specific endocytic receptors, but also the natural receptor ligands can be 
engineered to carry model antigens and thus be employed in DCs targeting strategies. Specifically, 
fusion of antigens to TLR2 (149) or TLR4 (150) ligands, or recombinant proteins encoding 
chemokines (MIP3α/CCL20) fused to established tumor antigens (151, 152) were shown to be 
effective in inducing antigen-specific CD8+ T cells responses and elicited protective anti-tumor 
immunity. 
Despite basic similarities between mouse and human DCs, it remains to be assessed whether the 
human homologues of the previously described receptors do play similar roles in vivo. Moreover, it 
remains difficult to directly compare human DC populations with mouse DC subtypes owing to 
differences in cell surface marker expression and to the fact that only few studies have analyzed 
human DC populations freshly isolated from tissues (140). 
 The DCs targeting approaches that are most likely to enter the clinic in the near future target 
DC-SIGN/CD209, DEC205/CD205 and the mannose receptor/CD206 (140). Although some reports 
have compared the distribution of these CLRs in different human tissues, it remains unclear whether 
DC-SIGN is the most DC-specific receptor or whether CD205 is unique in its distribution in the T 
cell area of lymphoid organs (153, 154). Indeed, several studies reported the effective induction of 
tumor specific antigen T cells responses by targeting human DCs via DC-SIGN and mannose 
receptor (155-157). Interestingly, a recent work by He and colleagues extended these in vitro 
observations to an animal model of transgenic mice expressing the human MR/CD206 (hMR Tg). 
Immunization of Tg mice with a recombinant anti-hMR mAb B11 fused to OVA, resulted in the 
adjuvant-dependent induction of effector T cells and antibody response able to protect the mice in 
tumor graft experiments (158). 
In a comparative study performed on human DCs, targeting CD205 was shown to be superior to DC-
SIGN and to CD206 in inducing proliferation and IFNγ production from antigen specific CD8+ T 
cells, supporting the hypothesis that CD205 receptor better allows access to the cross-presentation 
pathway (159). However, the identification of the most successful targeting candidate will indeed 
require a clear picture of the distribution of these receptor in various lymphoid organs and a better 
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Mice- Female C57BL/6 (B6) mice (6-7 weeks old) were purchased from Harlan (Milan, Italy). OVA 
specific, TCR transgenic OT-I and OT-II mice were purchased from the Jackson Laboratories. 
CD45.1 congenic C57BL/6 were bred to OT-I mice to obtain OT-I/CD45.1. Mice were housed at the 
ICGEB animal house. 
 
Cells- DCs were isolated from single cell suspensions of lymph nodes or spleen treated with 
400U/ml collagenase D (Roche) for 30 min followed by enrichment (depletion of B, T, NK) or 
positive selection by CD11c+ beads (Miltenyi Biotec). 
Langherhans and dermal DCs were isolated after washing C57Bl/6 ears once in 96% ethanol and 
three times in PBS. Dorsal and ventral part of the ears were separated and digested in a solution of 
PBS, 3% FCS, 0.5% Tripsin, for 45 min at 37°C. Epidermal and dermal layers were separated and 
cultured o/n in 24-well plates (one ear per well) in complete RPMI medium. Layers were discard and 
cells were recovered from supernatant. 
BMDCs were differentiated from BM precursors obtained from the femur of C57Bl/6 mice using 
either Fms-like tyrosine kinase 3 ligand (Flt3L) or GM-CSF. DCs were used at day 10 and purity of 
CD11c+ was higher than 90%. 
OT-II and OT-I cells were isolated from total lymph nodes suspension either by positive or negative 
selection using MACS® isolation kit.  
 
Cloning of 2.4G2 and DEC205 antibodies- RNA was prepared from 2.4G2 and NLDC-145 
hybridoma cells (~5x106) using the RNeasy Mini Kit (Qiagen). Upon standard RT-PCR reaction, the 
DNA fragment encoding for variable regions of rat anti-DEC-205 and anti-2.4G2 IgG antibodies 
were amplified using degenerated primers: mVHB and mCHγ for the VH region; and mCk2 and 
mVkB2 for the VL region. Upon cloning in pUC19 vector and sequencing, VL and VH regions were 
re-amplified using VL and VH families specific primers containing restriction enzyme sites 
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BssHII-VL 2.4G2: 5’ tatgcgcgcatgccgatgttcagatgacccagtct 3’ 
SalI-VL2.4G2: 5’ ataggtcgaccctttgatttccagcttggt 3’ 
XhoI-VL2.4G2: 5’ tatctcgagcaaaggtgaggtgcagctggtggagtcg 3’ 
NheI-VH2.4G2: 5’ tatgctagctccggaggagacagtgactgaaact 3’ 
 
BssHII-VLDEC205: 5’ tatgcgcgcatgccgatattgtgatgacccagtct 3’ 
SalI-VLDEC205: 5’ ataggtcgaccctttcaattccagcttggt 3’ 
XhoI-VLDEC205: 5’ tatctcgagcaaaggtgaggtgaaactgttggaat 3’ 
NheI-VHDEC205: 5’ tatgctagctccggaggagactgtgaccatgact 3’ 
 
Cloning of recombinant scFv-OVA257-264  in pDAN3 bacterial vector- The pDAN3 phagemid vector 
was modified by insertion of a linker between the sequences coding for SV5 and H6 tag, containing 
the restriction enzyme site AgeI and NsiI. An oligonucleotide containing the sequence coding for 
OVA class I peptide was then subcloned in the modified pDAN3 vector. 
Oligo used: 
Linker AgeI-NsiI UP: 
5’ ctagcggcaaaccaatcccaaacccactgctgggcctggataccggtatctttatgcatcccaccatcaccatcactaggc 3’ 
Linker AgeI-NsiI DOWN: 
5’ ggccgcctagtgatggtgatggtgatgcataaagataccggtatccaggcccagcagtgggtttgggattggtttgccg 3’ 
OVA UP: 5’ ccggtcttgagcagcttgagagtataatcaactttgaaaaactgactgaatggaccagtgatgca 3’ 
OVA DOWN: 5’ tcactggtccattcagtcagtttttcaaagttgattatactctcaagctgctcaaga 3’ 
 
Cloning of recombinant scFv-OVA257-264 in pcDNA3 vector- The pDAN3-DEC205-OVA257-264 
vector was modified by insertion of an oligo containing the restriction enzyme site ApaLI upstream 
the sequence coding for VLDEC205. The modified pDAN3 vector was then digested ApaLI/NotI. The 
fragment containing the entire sequence coding for DEC205 antibody fused to OVA257-264 was 
subcloned in pUT-SecIg vector downstream of the signal sequence of human IgG1. pUT-SecIg-
DEC205-OVA was finally digested HindIII/NotI and the fragment containing the scFv-OVA fusion 
was subcloned in pcDNA3 (Invitrogen). 
Oligo sequence: 
BAT UP: 5’ cgcgcgtgcactcggatattgtgctgacc 3’ 
BAT DOWN: 5’ gggtcagcacaatatccgagtgcacg 3’ 
A similar procedure was used for the cloning of pcDNA3-2.4G2-OVA257-264  construct. 
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Cloning of the scFvs isolated from the screening into pcDNA3 vector- The DNA sequence coding 
for the selected scFvs was isolated by digestion of pDAN3 vector with the restriction enzymes 
BssHII/NheI and subsequently cloned in the pcDNA3secIless-mEshortDcyto vector (available in the 
lab). The new scFv containing vector was then digested HindIII/BspEI and the isolated scFv 
subcloned into pcDNA3-OVA257-264 vector to produce the final scFv-OVA257-264 fusion. The sequence 
coding for scFv2E5-hγCH3 protein was obtained by digestion of pcDNA3-scFv2E5-OVA257-264 
vector with the restriction enzymes BspEI/NotI and subsequent cloning of the DNA fragment coding 
for third constant domain of human IgG1 (γ1-CH3). 
 
Cloning of the scFv/SIP full-length OVA fusion constructs- The pcDNA3Fc-OVA vector 
containing the sequence coding for ovalbumin (available in the lab) was modified by insertion of a 
linker containing the restriction enzyme NheI upstream the starting codon of OVA. The modified 
vector was digested with the restriction enzymes HindIII/XhoI to isolate the full-length sequence of 
OVA, which was then subcloned into pcDNA3 vector. The sequence coding for the various scFvs 
was isolated by digestion with the enzymes HindIII/NheI and then cloned upstream of OVA to 
generate pcDNA3-scFv-OVA vector.  
Oligo used: 
Linker NheI UP: 5’ agcttaatgctatgctagcggcggtac 3’ 
Linker NheI DOWN: 5’ cgccgctagcatagcatta 3’ 
 
To produce pcDNA3-SIP-OVA constructs the pcDNA3Fc-OVA vector was modified by insertion of a 
linker containing the restriction enzyme BamHI upstream the starting codon of OVA. The modified 
vector was digested with the restriction enzymes BamHI/XhoI to isolate the full-length sequence of 
OVA, which was then subcloned into pcDNA3-BCL1CH3∆Stop vector (available in the lab) to 
generate pcDNA3-SIP-OVA vector. 
Oligo used: 
Linker BamHI UP: 5’ agcttaatgctatggatccggcggtac 3’ 
Linker BamHI DOWN: 5’ cgccggatccatagcatta 3’ 
 
Rescuing phagemid libraries- The inculum size should be 10x library size in number of bacteria at 
the start, but should not exceed 0.05 O.D.600nm. The inoculum, generally 30µl of concentrated TG1 
bacteria, was transferred into 100ml of 2YT, 100µg/ml ampicillin, 2% glucose and grown with 
shaking (270rpm) for 1.5-2.5h at 37°C, to an O.D.600nm of 0.5. Bacteria were next infected with an 
appropriate amount of helper phage (20:1 phage/bacteria ratio) for 30 at 37°C with occasional 
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agitation. After the infection event, cells were pelleted for 10min at 4000 rpm and the supernatant 
removed. The bacterial pellet was resuspended in 100ml of 2YT, 100µg/ml ampicillin, 25µg/ml 
kanamycin and further incubated with shaking (270rpm) o/n at 30°C. The culture was spinned at 
4000rpm to pellet the bacteria. Phage in the supernatant were precipitated by adding 1/5 of the 
volume of PEG solution (20% Polyethylene glycol 6000, 2.5M NaCl) and left on ice for 1h. Phages 
were pelleted by spinning for 15 min, 4000rpm at 4°C. The pellet was finally resuspended in 1 ml of 
PBS and stored at 4°C. The standard yield is about 2-10 x 1012 from a 25 ml of culture. 
 
Phage Display Screening- Phages were prepared as previously described. Whole cell panning was 
performed by incubating 1013 cfu phage, pre-blocked in PBS/5% Milk, and 6 ×106 DCs, pre-blocked 
in PBS/1% Milk, for 2h at 4°C. After 2 washings in ice cold PBS/1% Milk followed by 2 washings 
in PBS, cells were resuspended in IMDM and incubated at 37°C for 30 min to allow phage 
internalization. Extracellular phages were inactivated with Subtilisin type VIII (3mg/ml) diluted in 
Buffer B (HBSS(-), 20mM Tris,2mM EDTA, pH8) for 30 min. Cells were washed and lysed in 1ml 
of triethylamine (100mM) for 8 min at RT. The lysate was neutralized with 0.5ml of Tris-HCl 1M, 
pH7.4. Internalized phages were recovered by infecting exponentially growing E.Coli (TG1) cells. 
Samples were then processed for quantitation of phage titer. 
 
BstN1 fingerprinting- Fingerprinting were carried out on variable regions amplified from individual 
clones using the primers: 
Fd seq= 5’ GAATTTTCTGTATGAGG 3’ 
M13rev= 5’ AGCGGATAACAATTTCACACA 3’ 
After amplification, each sample was digested for 2-3h at 60°C by incubation with a mix containing 
BstNI restriction enzyme. Digested samples were loaded on 2% Agarose TBE gel. 
 
FACS and Immunofluorescence Analysis Using Phages- Phages (1012 cfu ) were blocked in 
PBS/5%Milk and allowed to bind to BMDCs 1 h at 4 °C. For FACS analysis, phage binding was 
detected by anti-M13 IgG mAb (Amersham Pharmacia) and FITC-conjugated anti-mouse IgG 
(KPL). For confocal analysis, cells were plated on poly-L-lysine treated coverslips and incubated 
either at 4°C or 37°C for 30 min. After PBS washings, cells were fixed in 4% PFA and 
permeabilized with PBS/0.1% Triton. The coverslips were saturated with PBS/1%BSA (30 min at 
RT). Phage particles were detected with rabbit anti-fD Bacteriophage antibody (Sigma) and FITC-
conjugated swine anti-rabbit IgG (DAKO). Samples were analyzed by confocal microscopy 
(Axiovert; Carl Zeiss). 
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Biotinylation of membrane proteins and Receptor Immunoprecipitation- 107 BMDCs, WEHI or 
BO9 T cells were surface-biotinylated (Amersham ECL protein biotinylation system) following 
manufacturer directions. Briefly, cells were washed in PBS and resuspended in 1ml of biotinylation 
buffer. One µl of biotinylation reagent was next added and cells were incubated for 30 min at 4°C on 
orbital shaker. After being washed with cold PBS, cells were lysed in TNN buffer (50mM Tris, pH8, 
250mM NaCl, 0,5% NP-40) containing protease inhibitors. Cell debrids were spun out (12000 rpm, 
15 min) and supernatants were precleared with anti-SV5tag mAb (160) (10µg), and 200µl of 50% 
protein A-Sepharose CL-4B beads (Amersham Biosciences) for 2 h at 4 °C. Biotinylated proteins 
were IP with scFv-2E5 or scFv-ctrl (20µg/ml) for 2 h at 4 °C, followed by addition of 5µg of anti-
SV5tag mAb and 50µl of 50% protein A-Sepharose CL-4B. Beads were washed three times in ice-
cold TNN buffer before SDS-PAGE analysis. Upon transfer on PVDF membrane (Millipore), 
presence of biotinylated protein was revealed by HRP conjugated-streptavidin (Amersham). 
 
In-gel digestion and Mass Spectrometry- In-gel digestion was performed essentially as described in 
(161). Briefly, protein gel pieces were excised destained and tryptically digested with porcine 
trypsin. After incubation overnight (12–16 h), gel pieces were centrifuged at 14,000 rpm for 5 min, 
then extracted once with 5% formic acid/50% acetonitrile, dried by vacuum centrifugation, and 
stored at —20°C until ready for analysis. Mass spectrometry data were acquired working in 
reflectron mode with a 4800 MALDI TOF/TOF. A 0.5 uL aliquot of the peptide solution was mixed 
with 0.5 uL a-cyano-4- hydroxycinnamic acid matrix (Sigma, St. Louis, MO, USA) and subjected to 
MALDI analysis. MS data were subjected to database searching using Mascot (Matrix Science, UK) 
against Swissprot. Up to one missed tryptic cleavage and optional methionine oxidation and 
carbamidomethylation was considered. Mass accuracy was limited to 80 ppm. 
 
Cloning of murine CD36 cDNA- Total RNA was prepared from WEHI231 B cells (~5x106) using the 
RNeasy Mini Kit (Qiagen).. Full-length CD36 cDNA was produced using the specific primers: 
CD36 HindIII= 5’ AAAGCTTGCACGGGAGAATGGGCTGT 3’, 
CD36 XhoI= 5’ CCTCGAGACTACTTATTTTCCATTCTTGGATTT 3’. 
CD36 cDNA was subcloned pcDNA3 vector (Invitrogen) using HindIII and XhoI as restriction 
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HEK293T cell transient transfection with calcium phosphate- Cells were plated in 6-well Petri 
dishes. Fresh medium was added 4h before transfection. 5µg of plasmidic DNA was resuspended in 
50µl of 0.1X TE (10mM Tris, 1mM EDTA). Mix A was prepared by addition of 169µl of deionized 
water, 5µl of CaCl2 2M and drop by drop plasmidic DNA and 26µl of CaCl2 2M. The mix A was 
added drop by drop to 250µl of 2X HBS (280mM NaCl, 10mM KCl, 1.5mM NaH2PO4, 12mM 
dextrose and 50mM Hepes). Total mix was added to cells drop by drop. Cells were incubated o/n at 
37°C and then medium was replaced. 2 days later, cell and/or supernatants were collected and 
analyzed. 
 
Expression of scFv-OVA recombinant proteins in bacteria- pDAN3-scFv-OVA plasmids were used 
to transform the E.coli strain HB2151. Bacteria were grown in 2YT ampicillin medium at 37°C to 
0.7 O.D.600nm Upon induction with 0.5mM IPTG, bacteria were incubated for 5h at 30°C. The 
scFv periplasmic fraction was prepared by osmotic shock. Pelleted bacteria were resuspended in 
PPB buffer (200mg/ml sucrose, 1mM EDTA, 30mM TrisHCl pH 8) and left in ice for 20 min. After 
centrifugation the supernatant was collected and the cells resuspended in 5mM MgSO4 buffer for 20 
min. The solution was centrifuged and both supernatants pooled and dialyzed against PBS. 
 
PolyH6 tag protein purification-Recombinant scFv-OVA proteins were purified by affinity 
chromatography using polyH6 tag purification system (Ni-NTA His Bind Resin, Novagen) following 
manufacturer procedure. Briefly, scFv-OVA proteins, either obtained from periplasmic extract of 
HB2151 E,coli cells or from supernatants of 293T transfected cells, were dialized o/n against a 
solution of 30mM Tris/HCl, 300mM NaCl, pH8. PBS washed Ni-NTA resin was next added to the 
dialized proteins and incubated for 1,5h at 4°C on orbital shaker. After binding, samples were 
centrifuged 2 min at 3000 rpm and the supernatant discard. Samples were washed once with a 
solution of 30mM Tris/HCl; 100mM NaCl, 20mM Imidazol, pH8. Finally, proteins were eluted from 
the resin by incubation with a solution of 30mM Tris/HCl; 100mM NaCl, 250mM Imidazol, pH8. 
Eluted proteins were then dialized o/n against PBS. 
 
SIP-CD36-OVA Internalization Assay- DCs were incubated with SIP-CD36-OVA for 1h at 4°C, 
washed and then either kept at 4°C or incubated at 37°C for 15, 30 or 60 min. For FACS analysis: 
the level of SIP-CD36-OVA remaining at the cell surface was detected using rabbit anti-OVA and 
FITC-conjugated goat anti-rabbit IgG (KPL). The median fluorescent values of OVA+ cells was 
determined and used to calculate the % remaining scFvCD36-OVA at the surface, with 1 h 4°C 
incubated cells taken as 100%. For confocal analysis: after binding at 4°C for 1h, cells were washed, 
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plated on poly-L-lysine treated coverslips and incubated either at 4°C or 37°C for 30 min. 
Membranes were counterstained with 5µg/ml cholera toxin subunit B-FITC washed, fixed in 4% 
PFA and permeabilized with 0.02% saponin. ScFvCD36-OVA was detected with Alexa Fluor 594-
F(ab')2 goat anti-human IgG (Molecular Probes). 
 
In vitro T cell Proliferation Assay - DCs were pulsed with graded doses of scFv/SIP-OVA proteins, 
soluble OVA (Worthington biochemical Corp., Lakewood, NJ, USA) or OVA257-263 peptide for 4h at 
37°C. After washing, 1×105 OT-I or OT-II cells were co-cultured with Ag pulsed DCs in round 
bottom 96-well plate (1:5 DC/T cell ratio). After 2d, [3H]thymidine (1µCi; Amersham Biosciences) 
was added for 18 h, and incorporation was measured by liquid scintillation counting after collection 
of cells on a glass fibre filter with and automatic cell harvester (Tomtec, Calif., USA). Alternatively, 
CFSE labeled (1µM) OT-I cells were added to pulsed DCs (1:2 DC/T cell ratio) and proliferation 
evaluated 3 d later as CFSE dilution. 
 
Adoptive Transfer and T Cell Proliferation Responses- OT-I or OT-II cells were labeled with 7µM 
CFSE according to manufacturer instructions. C57BL/6 mice were i.v injected with 1-2 x106 OT-I or 
OT-II cells followed by injection in the footpad of scFv/SIP-OVA proteins. 3 d later, lymph nodes 
cell suspensions were stained for CD8 or CD4 respectively and CFSE dilution evaluated by FACS. 
To evaluate long term OT-I persistance, 2x106 OT-I/CD45.1 were injected i.v. into recipient CD45.2 
host, immunized with scFv-OVA proteins. 12 d later, spleen and lymph node cells suspension were 
stained with anti-CD8 and anti-CD45.1 to evaluate OT-I cells number. 
 
In Vivo Citotoxicity Assay- C57Bl/6 mice were s.c immunized with 0,1µg of recombinant SIP-
CD36-OVA or SIP-Ctrl-OVA proteins. After 12 days, mice were i.v injected with target 
spleenocytes, prepared as follow: naïve syngenic spleenocytes were pulsed with OVA257-264 peptide 
(5µM) (1h at 37°C), washed and labeled with high concentration (5µM) of CFSE. The non-pulsed 
control spleenocytes were labeled with low concentration (0,5µM) CFSE. Both CFSEhigh and 
CFSElow-labeled cells were mixed at 1:1 ratio (7 ×106 cells of each population) and injected i.v. into 
mice. The number of CFSE positive cells remaining in the spleen and lymph nodes after 15h was 
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Intracellular IFNγ staining- Intracellular IFNγ production by primed CD8+ T cells was evaluated 
using bulk splenocytes, lymph node cells or blood cells cultured for 5h with 1µM of SIINFEKL 
peptide or medium alone in the presence of brefeldin A (7µg/ml)(BD Biosciences). Cells were 
stained with anti-mouse CD8 Ab and anti-CD45.1 Ab for 25 min at 4°C. After fixation with 2% 
PFA, cells were stained for intracellular IFNγ in PermWash solution (BD Biosciences) for 30 min at 
4 °C. 
 
Anti-OVA Ab ELISA- 96-well Maxisorp ELISA plates (Nunc) were coated o/n with 3µg/ml OVA. 
Plates were washed and blocked in PBS/1%BSA/0.1%Tween20. Sera collected from the clotted 
blood of immunized mice were serially diluted 1/100 to 1/12,800 in blocking solution and incubated 
1h at RT. Plates were washed and Ab binding was detected using HRP-conjugated anti mouse IgG 
antibody (KPL) followed by tetramethylbenzidine peroxidase substrate (Sigma). 
 
Tumor rejection experiments- Mice were injected in the footpad on day 0 and 7 with 0,5µg of SIP-
CD36-OVA (6 mice), SIP-Ctrl-OVA (6 mice) or left untreated (4 mice). 7 d after the second 
immunization, each mouse was challenged s.c with 2x105 EG7-OVA cells (ATCC: CRL-2113). 
Tumor size was measured with a caliper ruler 14, 21 and 28 days after the challenge. Average size is 
expressed in cubic millimeters using the formula V=(length × width2)/2. Significance of protection 





















3.1 Screening of a scFv phage library on mouse Dendritic Cells 
3.1.1 The Phage display technology 
 The phage display technology allows the presentation of large combinatorial libraries of 
peptide or proteins on the surface of filamentous phage. The ligand is displayed on the surface of the 
phage by fusing its gene to the phage genome, thus providing a physical linkage between the 
phenotype and the genotype. In case of antibodies libraries, the displayed proteins are generally 
fused to the N-terminus of the phage coat protein pIII. 
To reduce the interference of the foreign moiety with phage assembly and infectivity, a phagemid 
display system was developed. A phagemid is a plasmid that encodes for the recombinant pIII-fusion 
protein and contains the packaging signal of filamentous phage. It produces large amount of the 
recombinant displayed proteins, but it is unable to assemble progeny phage, unless the bacteria 
carrying the phagemid also contain a helper phage, which supplies the other protein required for 
virion assembly. 
 Antibody phage display is accomplished by fusing the coding sequence of the antibody 
variable (V) regions to the pIII phage protein. A single-chain variable fragment (scFv) is a single 
polypeptide chain that contains one light chain variable region (VL) joined to one heavy chain 
variable region (VH) by a flexible linker. The linker, usually 15-18aa long, allows the association of 
the VL and VH to form the antigen-binding site. Functional scFv are expressed on the surface of the 
infective particles while the encoding genes reside within the phage. The linkage between antibody 
genotype and phenotype allows the enrichment of antigen specific phage antibodies. 
 Antibody library are screened and enriched for antigen-specific clones by a technique known 
as bio-panning, in which scFv-phage particles are incubated with the antigen of interest. When the 
target antigen is difficult to express and purify (i.e. membrane proteins) or it is still uncharacterized 
(i.e. novel cell markers), the panning can be performed directly on cell surface or tissue sections. 
Whole cell panning is useful for the identification of antigen that are only expressed on specific cell 
subsets (162) and it has the advantage of focussing on accessible and biologically relevant epitopes 




3.1.2 Setting up of the screening procedure 
 In this work, we took advantage of the phage display technology to isolate antibodies 
directed against DCs surface molecules. We decided to apply a whole cell panning procedure to 
specifically select antibodies able to trigger the internalization of the bound DCs receptor. 
To take advantage of the phage display technology in targeting endocytic receptors, phage vectors 
should be internalized upon receptor binding, capable of being rescued from cells and amplified for 
subsequent rounds of selection. To set up the conditions to selectively recover internalized phages 
when mixed to a pool of not internalizing ones, we initially engineered two phagemid vectors 
displaying antibody fragments (scFv) that recognize known DCs endocytic receptors. 
We chose two antibodies directed against well characterized families of endocytic receptors: the Fc 
gamma receptor family and the C-type lectin family of receptors. More specifically, we selected the 
mAb 2.4G2 that recognizes mouse FcγRIIb and FcγRIII (167, 168) and the mAb NLDC-145 directed 
against the receptor DEC-205 (169). 
 The variable regions of 2.4G2 and NLDC-145 were amplified and engineered in the scFv 
format. Both scFvs were subsequently subcloned in the phagemid vector pDAN3 to allow the display 
on phage particles as fusion with the pIII coat protein. 
pDAN3 vector also enables the production of the scFv as soluble protein when expressed in a 
“nonsuppressor” strain of E.Coli cells (i.e.HB2151). These cells recognize an amber stop codon 
inserted between the scFv gene and the gene coding for pIII, thus allowing the expression of the 
scFv without the pIII protein (Fig.1). Such soluble protein is secreted into the periplasmic space of 











Figure 1. Schematic representation of the phagemid vector pDAN3. Single-chain 
antibody fragments can be either displayed on the surface of phage particles as fusion with 
the coat protein pIII, or produces as soluble proteins when expressed in “nonsuppressor” 
E.coli strains. 
Soluble or dispalyed proteins 
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Binding and Internalization of scFv2.4G2 and scFvDEC205 by BM-DCs 
 Phage particle displaying scFv2.4G2, scFvDEC-205 or a control scFv (scFvCtrl) directed 
against an irrelevant Ag, were produced and quantified following standard protocols. To evaluate the 
efficiency of display of the fusion pIII-scFv proteins, we performed Western Blot analysis using a 
mAb against the SV5 tag fused to the expressed scFv. The expected size for the recombinant pIII-
scFv protein is around 105kDa, while for the pIII alone is around 75kDa. As shown in Fig.7, all the 
pIII-scFv fusions were properly displayed on the fd phage. 
The selected scFv were also expressed in the “nonsuppressor” E.Coli strain HB2151 as soluble 
proteins and subsequently purified from periplasmic extracts by means of the His6 tag. ScFv proteins 












 To assess the functionality of scFv2.4G2 and scFvDEC-205, we performed a flow cytometry 
analysis on bone marrow derived DCs. As shown in Fig.3a and 3b, both scFv2.4G2 and 
scFvDEC205 displayed on fd phage retain their binding ability to FcγRs and DEC-205 receptor 
respectively, whereas no binding is observed with scFvCtrl-phage. 
 To assess whether BMDCs internalize scFv2.4G2 phagemid through receptor mediated 
endocytosis, we performed a series of analysis using both flow cytometry and confocal fluorescence 
microscopy. In a first set of experiments, BMDCs were incubated with scFv2.4G2-phage or 
scFvCtrl-phage at 4°C to allow binding and after extensive washing, cells were either kept at 4°C or 
incubated at 37°C. 30 minutes internalization time was chosen to allow the active endocytosis of the 
bound receptor and at the same time to prevent the inactivation of the internalized phage in the 
acidic cellular compartments (171). Upon incubation of DCs at 37°C, we observed a reduction in 
scFv2.4G2-phage staining indicating the effective internalization of the phagemid. As expected, no 
binding on DCs was detected with scFvCtrl-phage (Fig. 3c). To exclude the possibility that the 
Figure 2. Production of phage 
particles displaying specific scFv 
proteins. Western blot analysis of 
scFv-2.4G2, scFv-DEC205 and 
scFv-Ctrl displayed on phage (upper 
panel) or produced as soluble 




decrease in surface staining was due to dissociation of scFv2.4G2 from FcγR rather than specific 
internalization, we analyzed the cells by confocal fluorescence microscopy. Upon phage binding and 
internalization, cells were permeabilized and stained with the anti-fd bacteriophage Ab. Intracellular 
staining was detected only in cells treated with phages displaying the scFv2.4G2 and not the 


















Recovery of internalized scFv 2.4G2 phagemid from BMDCs lysates 
 Selection of internalized phages from a phage library requires the optimization of the 
screening in order to increase the enrichment of specifically internalized phages over non-
internalized ones. Whereas nonspecifically or weakly bound phages can be removed by several PBS 
washings, in case of phages bound to cell surface molecules that do not undergo internalization a 
stronger treatment is required. At first, we tested whether washing BMDCs with a low pH glycine 
buffer may favor the dissociation of scFv 2.4G2-phagemid bound to the cells surface. Despite this 
procedure has been previously applied for the selection of internalizing antibodies from phage 
library (164, 172), we found that the low pH buffer severely damaged BMDCs, shown by the cell 
profile in FACS analysis in (Fig. 4a). In a second set of experiments, we tested the protease 
subtilisin to specifically inactivate extracellular phages. Subtilisin has been shown to proteolyze the 
Figure 3. Functionality of scFv-
2.4G2 and scFv-DEC205
phagemid. Binding of 
recombinant scFv-2.4G2 and scFv-
DEC205 phages to BMDCs 
detected with an anti-phage mAb 
(a-b); FACS (c) and confocal (d) 
analysis of scFv-2.4G2 phage 






phage protein pIII, thus leaving the phage particles non-infectious (173). We evaluated subtilisin 
activity on scFv2.4G2 phagemid bound to BMDCs. Cells were either treated or not with a solution 
containing the protease for 30 min, before lysis. The phage titre was then evaluated by infection of 
E.Coli cells. Subtilisin treatment is effective since it reduced the phage titre of the treated sample at 
less than 2% respect to the non treated one. Viability of the cells upon subtilisin incubation was 
evaluated by FACS using propidium iodide to stain dead cells. We did not observe a difference in 












 Based on these preliminary results we moved to test the conditions that allow recovery of 
internalized scFv2.4G2 when mixed to a pool of irrelevant phages (scFvCtrl). BMDCs were 
incubated with a mix of scFv2.4G2 and scFvCtrl phage at 1/100 or 1/1000 ratio. Upon 
internalization and subtilisin treatment, cells were lysed and used to infect E.coli cells. To evaluate 
the enrichment of scFv2.4G2 against scFvCtrl phage, we performed a DNA fingerprinting analysis. 
DNA from single clones derived from E.Coli infections was subjected to PCR using a specific set of 
primers to amplify the scFv region. The amplified DNA was then treated with the restriction enzyme 
BstN1 to obtain a pattern of digested fragments that is sequence specific and thus allows to 
distinguish different scFv. The experiment was repeated several times and analysis of the recovered 
clones indicated that we could achieved a 20 to 100 fold enrichment of the scFv2.4G2 for a single 






Figure 4. Effects of acidic/subtilisin treatment on BMDCs viability. FACS profile of 
BMDCs incubated with a low pH glycine buffer (a); propidium iodide staining of BMDCs 
treated with subtilisin (b). 
Figure 5. Enrichment of internalizing phage 
particles. Representative fingerprinting pattern 
obtained after phage internalization assay. I: 
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3.1.3 Selection of internalizing phages by panning on BM-DCs 
 Having defined the conditions for the internalization and the recovery of a model 
endocytosed phage, we next set out the screening to identify internalizing scFv phages from a highly 
diverse human scFv-phage library (>1010 independent clones) (174). The diversity of the library was 
confirmed by BstN1 DNA fingerprinting. More than 80% of clones contained a full length scFv and 








We decided to carry out a first screening on in vitro differentiated BMDCs, in order to easily obtain 
a large amount of cells. We used immature DCs since upon maturation they have been shown to 
downregulate the antigen internalization capacity (9).Both DCs (107 cells) and the phage preparation 
(~1013cfu) were pre-blocked with a solution of PBS and skimmed milk and were allowed to bind at 
4°C for 2h. The stringency and number of the washings was increased in each round of selection to 
favor the enrichment of clones with higher affinity. Upon internalization, cells were treated with 
subtilisin, washed and finally lysed in TEA. Cell lysates were used to infect E.coli cells to recover 
and amplify phages for the next round of selection. A total of three rounds of panning were 











Figure 7. Schematic representation of the 
phage panning procedure. Phages were 
allowed to bind to DCs and to be 
internalized by incubation at 37°C. Not 
internalized phages were inactivated by 
subtilisin treatment. DCs were lysed to 
recover internalized phages by infection of 
E.Coli cells. Rescued phagemids were used 
for the next round of selection.  
Figure 6. ScFv phage library diversity. 
Fingerprinting pattern of 12 randomly 
picked clones from the human scFv-phage 
library used in the screening. 
MW  1    2    3    4    5    6    7    8    9   10   11   12  MW 
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 To initially evaluate the enrichment for scFv-phages recognizing DCs surface antigens, we 
analyzed the pool of clones recovered after each round of selection by flow cytometry. The 
polyclonal scFv-phage population from the third round of panning, compared to the pools of the first 
and second round, showed significantly increased binding on DCs indicating the presence of 
BMDCs specific scFv-phages (Fig. 8a). We next evaluated the binding of the three pools of phages 
to a different cell type: the B cell line A20. Although a slight increase in surface staining is detected, 
there is no significant enrichment of binders in the phage pool from the third round compared to the 









 To determine whether the selected scFv-phages were internalized, we performed 
immunofluorescence analysis using confocal fluorescence microscopy. Intracellular staining was 
revealed upon incubation at 37°C of DCs with the polyclonal scFv-phage population from the third 
round of panning suggesting that most of the isolated ligands were targeting endocytic receptors. As 
expected, no staining was detected upon incubation of the cells with the un-screened scFv-phage 
library (Fig. 8c). 
a) b)
Figure 8. Evaluation of the phage panning procedure. Flow cytometry 
analysis on DCs (a) and A20 B cells (b) to monitor the enrichment of binders in 
the polyclonal phage preparations from each round of selection. (c) 
Internalization of phage particles by DCs incubated with the original library or 





Characterization of selected scFvs 
 In light of the binding data from the flow cytometry, we next randomly picked 40 individual 
phage clones from the third round of panning and further analyzed them by DNA finger-printing and 
DNA sequencing. Ninety percent of the clones contained a full length scFv. We could identify 7 
different fingerprint patterns with one being mostly represented: scFv-2 which recurred with a 
frequency of 60% (Fig. 9). The clones were sequenced and the VH and VL family obtained were 
assessed by screening against the VBASE database. Notably, all the clones but one (scFv-4), which 
contained rearrangements and was not functional, carried a VH belonging to the VH 1 family and a 
VL to the Vλ 1 family. The length of the CDRs H3 was rather short (ranging from 9 to 11 aa) and 















Figure 9. Diversity of the pool of scFv clones isolated after three rounds of selection.
BstN1 fingerprinting of randomly picked single clones from the third round of selection. 
ScFv clones with a different fingerprinting profile are indicated in blu. 
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 We next assessed the quality of the clones at the phenotypic level by Western Blot analysis. 
As shown in Fig. 10a, most the clones were well displayed on the phagemid and were expressed as 
soluble recombinant scFv proteins. FACS and immunofluorescence analysis on BMDCs were next 
performed to evaluate the binding and the internalization of each clone. All the displayed scFvs 
isolated from the screening were able to bind to DCs and showed a similar staining profile, 
moreover, they were efficiently internalized (Fig. 10b-c). We have therefore provided the proof of 




























Figure 10. Analysis of scFv clones isolated 
from the screening on BMDCs. Western Blot 
analysis to evaluate the display of the selected 
scFv on phage surface, revealed with anti-SV5 
mAb (a). FACS analysis to monitor the binding 
of single clones on DCs (b). Immunofluorescence 
analysis to confirm the internalization of the 
selected clones (c). Phage binding and 





3.1.4 Selection of internalizing phages by panning on splenic DCs 
 DCs are a phenotypically heterogeneous population of cells both in mice and in humans. DCs 
generated in vitro by supplementing GM-CSF resemble monocyte-derived DCs. However, it is 
unclear whether they correspond to any of the lymphoid-organ-resident DCs subsets found in steady 
state in vivo (7). Therefore, we decided to perform a new screening on freshly isolated splenic DCs. 
DCs were isolated from the spleen of C57Bl/6 mice and purified by magnetic sorting. The panning 
was carried out as previously described. Upon binding and internalization, extracellular phages were 
inactivated by subtilisin treatment. Cell lysate were used to infect TG1 cells to amplify phages for 
the next round of selection. A total of three rounds were performed. 
We evaluated the enrichment of binders by FACS analysis and found that only a percentage of 
CD11c+ DCs stained positive for the pool of phages recovered from the third round of selection, 






Fingerprinting analysis of 36 randomly picked clones revealed that 97% of them contained a full 
length scFv. We were able to identify 4 different fingerprinting patterns with three of them being 
more represented: clone1, 11 and 3 with 33%, 24% and 21% of frequency respectively (Fig. 12). 
Sequence analysis revealed a similarity between the clones. By searching against VBASE database 
we found that all the VH sequences belonged to the VH 1 family and the VL sequences to the Vλ 1 
family. The CDRs H3 region length ranged from 9 to 11 aa and was identical in the last 5 aa in the 
most represented clones (scFv-1, scFv-3 and scFv-11) Only in one clone (scFv-9) that recurred only 






Figure 11. Evaluation of the phage panning procedure. Flow cytometry analysis 
on splenic DCs to monitor the enrichment of binders in the polyclonal phage 
preparations from each round of selection.
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Each clone was phenotypically functional and well displayed on the phagemid (Fig. 13a). FACS 
analysis showed that all the scFv-phage selected were able to bind to a percentage of splenic purified 




























Figure 12. Diversity of the pool of scFv 
clones isolated after three rounds of 
selection. BstN1 fingerprinting of 
randomly picked single clones from the 
third round of selection. ScFv clones 
with a different fingerprinting profile are 
indicated in blu. 
b)
Figure 13. Analysis of scFv clones isolated from the screening on splenic DCs. Western 
Blot analysis to evaluate the display of the selected scFv on phage surface, revealed with 
anti-SV5 mAb (a). FACS analysis to monitor the binding of single clones on DCs using an 




3.2  Receptor identification 
 The analysis of the scFvs recovered from the panning on splenic DCs and BMDCs revealed a 
sequence identity between the two most represented clones of each screening (scFv-1 and scFv-2 
respectively). This strong selective pressure may derive from the high level of expression of the Ag, 
either a receptor or a specific structure/domain shared by different surface molecules, in both 
BMDCs and splenic DCs. Alternatively, a higher stability of the dominant scFv-phagemid may have 
conferred a growth advantage and thus favoured its amplification in each round of selection. Indeed, 
the sequence similarity and the constant CDR H3 length of the scFvs isolated from both screenings 
may denote a peculiar conformation of the Ag binding site and suggest an identity in the type of 
structure recognized by each clone. In light of these findings, it was of primary interest to 
characterize the Ag recognized by the dominant scFv, designated scFv-2E5 hereafter. 
 To this purpose, we pursued two complementary approaches. In a first set of experiments, we 
set out to precisely define the pattern of expression of the Ag recognized by scFv-2E5 on different 
DCs subsets and on other cells of hematopoietic origin. In parallel, we carried out 
immunoprecipitation experiments and mass spectrometry analysis to unequivocally identify the 
nature of the Ag. 
 
 To obtain a large amount of properly folded protein and avoid the purification step from 
E.coli periplasmic extract, we expressed both scFv-2E5 and a scFv-Ctrl in mammalian cells by 
stable transfection. 
By genetically linking the variable regions of the scFv to the third constant domain of human been 
shown to be well secreted from mammalian cells by means of its human IgG1 secretion signal 
sequence(175).  
Cell supernatants containing either scFv-2E5-CH3 or a scFv-Ctrl-CH3 proteins were thus used to 
assess the expression of the putative receptor on different cells type. Notably, the γ1-CH3 is a 
suitable tag for binding detection and due to its lack of binding to FcRγ it does not require a pre-





3.2.1 Binding of scFv-2E5 on DCs subsets 
 We initially evaluated the binding of scFv-2E5 on the different DCs subsets found in various 
lymphoid organs: spleen, lymph nodes (either peripheral and mesenteric)and thymus DCs subsets 
were identified by the differential expression level of specific cell markers such as: CD11c, CD8, 
CD11b and B220. Upon treatment of the organs with collagenase/DNaseI, the DCs population was 
enriched by low-density fractionation and recovered cells were incubated with either scFv-2E5 or 
scFv-ctrl. After extensive washing, scFv-2E5 binding was revealed using an anti-human IgG Ab and 
evaluated by gating on the different DCs subtypes. As shown in figure 14a, analysis of the 
conventional DCs, derived from both spleen and lymph nodes and defined as CD11chi cells, revealed 
a tight correlation between CD8α expression and binding of scFv-2E5, resulting in two predominant 
populations of DCs: CD8α+ scFv-2E5+ and CD8α-scFv-2E5-. Plasmacytoid DCs, defined as B220+ 
and CD11cint, did not shown any specific staining, indicating the lack of expression of the receptor 
recognized by scFv-2E5 on this specific subset. Analysis of the so called migratory DCs: 
Langherhans and dermal DCs from peripheral LNs and DCs from lamina propria (mesenteric LNs), 
was evaluated by gating on a population of CD11c+ cells that expresses high levels of MHC class II. 
We could not detect any staining on these migratory DCs suggesting the lack of expression of the Ag 
recognized by scFv-2E5. We confirmed this finding, by repeating the analysis on Langerhans and 
dermal DCs isolated from epidermis. Altogether, these results indicate that the antigen recognized by 
scFv-2E5 is uniquely expressed by the CD8α+ subset of lymphoid organ resident DCs. 
 
3.2.2 Binding of scFv-2E5 on hematopoietic cells 
 We next investigated scFv-2E5 binding specificity for other hematopoietic cell types present 
in the spleen. We evaluated the binding on B cells, T cells, monocytes and macrophages (Fig. 14b) 
using a panel of different Abs: B220, CD3, Ly6c, CD11b, and F4/80. Whereas both T lymphocytes 
(CD3+ cells) and monocytes (defined by gating on CD11b+ and Ly6c+ cells) were negative, we could 
detect scFv-2E5 binding on both macrophages (F4/80hi and Ly6c+) and on a percentage (30%) of B 
cells. Altogether, these data indicate that scFv-2E5 recognizes a cell surface marker specifically 
expressed by antigen presenting cells. 
 We next analyzed scFv-2E5 binding on two different B cells lines: A20 (IgG expressing 
mature B cells) and WEHI (immature IgM expressing). As shown in figure 14c, scFv-2E5 clearly 
stained WEHI, but not A20 cells. Although this analysis is not sufficient to unequivocally link the 
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receptor expression to the cell maturation state, it indicates that at least in B cells, the expression of 
































Figure 14. Binding profile of scFv-2E5 on splenic DCs and hematopoietic 
cells. DCs from the spleen of C57BL/6 mice were labelled with scFv-2E5 and a 
panel of different markers gating on: CD11chi and CD8α+/- for conventional DCs, 
and CD11cint and B220+ for plasmacytoid DCs. Langherhans and dermal DCs 
were isolated from the epidermis, and identified by gating on CD11c+ cells (a). 
Monocyte were defined by gating on Ly-6Chi, CD11bhi and CD11c- cells, 
macrophages as F4/80+ and Ly-6Cint, B lymphocytes by expression of B220 and T 
cell by expression of CD3 (b). Filled line, scFv-2E5. Binding profile on the B 
cells line A20 and WEHI (c). 
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3.2.3 Antigen identification 
 To define the nature of the antigen targeted by scFv-2E5, we performed immunoprecipitation 
(IP) experiments using extracts of BM-DCs and WEHI B cell line. In order to visualize the IP 
antigens, cell surface proteins were biotynilated before preparing cell lysate. Cell extracts were 
incubated with scFv-2E5 or an irrelevant scFv (scFv-control). Upon IP, presence of biotinylated 
surface proteins was revealed in a western blot analysis by streptavidin. These experiments identified 
a DCs specific protein with an apparent molecular masses of 90kDa. The same experiment 
performed on WEHI cells revealed a band of approximately 100kDa, that may indicate a cell type 
dependent post-translational modification. As further control, we repeated the IP on biotinylated 
extracts from a T cells line (BO9) that was negative for scFv2E5 binding. As expected, Western Blot 
analysis did not reveal any biotinylated protein (Fig. 15a). 
 For precise receptor identification, nonbiotinylated cell extracts were IP and separated by 
SDS-PAGE. MALDI Mass Spectrometry was used to analyze the IP proteins with a molecular mass 
corresponding to the band previously revealed by Western Blot. Protein gel pieces were excised and 
tryptically digested. Extracted peptides were mixed with α-cyano-4- hydroxycinnamic acid matrix 
and subjected to MALDI analysis. Mass spectrometry data were acquired with a MALDI TOF/TOF 
and subsequently subjected to database searching using Mascot program against Swissprot. Protein 
data base searching revealed that the primary sequence of the peptides obtained from trypsin 
digestion matched portions of mouse class B scavenger receptor CD36 (Fig. 15b). To validate the 
results from MS we carried out a series of Western Blot analysis. 
CD36 is a highly N-glycosilated protein and indeed treatment with the amidase PNGaseF, to 
specifically remove N-linked glycans, revealed a band of approximately 55kDa, which correspond to 
the molecular mass of CD36 (Fig. 15c). We next repeated the IP experiment on biotynilated or not 
biotinylated cells extracts and compared the IP proteins using either streptavidin or an anti-CD36 
antibody. The commercial Ab detected a specific band that likely coincided with the one revealed by 
streptavidin (Fig. 15d). To further confirm the identity of the antigen recognized by scFv-2E5, full-
length cDNA sequence of CD36 was amplified and transfected in 293T cells. FACS analysis showed 
that scFv-2E5 specifically stained CD36-transfected but not mock transfected 293T cells (Fig. 15e). 
These results thus demonstrate that scFv-2E5 indeed recognizes an epitope in the extracellular 
portion of CD36. 
 
 To prove our initial hypothesis that the scFvs similarity in the CDR H3 region was correlated 
to the specificity of the Ag recognized, we repeated the FACS assay on CD36-transfected 293T 
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cells. We tested two scFvs, isolated from the screening on splenic DCs, whose CDR H3 (last 5 aa) 
were either similar (scFv-3) or different (scFv-9) from scFv-2E5. Whereas scFv-3 clearly stained 
CD36-transfected 293T cells proving the specificity of this scFv for the receptor, in case of scFv-9 
we did not observe any binding (Fig. 15f). This result indicates that the CDR H3 region do play a 
critical role in defining the Ag specificity and suggests that the other scFvs, isolated from both the 
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Figure 15. ScFv-2E5 recognizes an epitope in the extracellular portion of the scavenger receptor 
CD36. Western blot of extracts from cell-surface biotinylated DCs, WEHI or BO9 T cells, 
immunoprecipitated with scFv-2E5 (2E5) or an irrelevant scFv (ctrl) and revealed with streptavidin-
HRP (a) Graphic representation of the data obtained from Mass Spectrometry analysis of the proteins 
immunoprecipitated by scFv-2E5 (b). Western blot of extracts from biotinylated WEHI cells upon 
immunoprecipitation with scFv-2E5 or scFv-ctrl and PNGaseF treatment. IP proteins were revealed 
with streptavidin-HRP (c). Western blot of extracts from biotinylated DCs or BO9 T cells, 
immunoprecipitated with scFv-2E5 or scFv-ctrl and revealed with streptavidin-HRP or an anti-CD36 
Ab, as indicated (d). Binding of scFv-2E5 or scFv-ctrl to 293T cells transiently transfected with the 
cDNA encoding mouse CD36 (e). Binding of different scFvs isolated from the screening to 293T cells 
transfected with CD36 cDNA (f). 
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3.3 Antigen presentation efficiency of the antibody/receptor pairing 
 Results described in the previous sections provide the proof of principle that antibodies 
directed against DCs endocytic receptors can be isolated by phage-display and subsequently used to 
identify the cognate receptor. 
Having isolated a high affinity antibody against CD36, a multiligand scavenger receptor with a role 
in the uptake of apoptotic bodies and in innate immunity, we decided to characterize in detail the 
immune responses elicited by targeting this receptor on DCs. 
 To evaluate the capacity of the antibody/receptor pairing to deliver antigens to the cellular 
compartments involved in Ag processing and presentation, we designed a DNA cassette that allows 
us to readily produce recombinant scFv proteins that include the antigenic epitopes. We chose as a 
model antigen ovalbumin and evaluated the immunogenicity of different scFv-OVA fusion proteins 
containing either the single MHC class I OVA epitope (scFv-OVA257-264) or the whole OVA protein. 
In the latter case, we produced both a monomeric (scFv-OVA) and a dimeric form (SIP-OVA) of the 
recombinant OVA proteins to allow receptor cross-linking. Finally, we tested all these molecules for 
their antigen presenting properties in different set of in vitro and in vivo assays. 
 
3.3.1 Production of scFv-OVA257-264 epitope fusion protein 
 To produce our recombinant OVA fusion proteins, we initially modified the phagemid vector 
pDAN3 by cloning between the two tag sequences (SV5 and His6) a short linker containing two 
restriction enzyme sites: AgeI and NsiI. We chose these sites because of their low frequency of 
recurrence in the DNA coding for the variable regions of antibodies. This DNA cassette thus allows 
to insert in frame with the scFv any desired antigenic epitope flanked by the sequence of the two 
restriction enzyme sites. 
Ovalbumin was chosen as model antigen due to the availability of well characterized systems to 
evaluate Ag processing and presentation on both MHC class I and MHC class II molecules. 
To test the efficiency of different scFvs to target antigens to the cross-presentation pathway, we 
cloned in the DNA cassette the sequence coding for the ovalbumin class I epitope SIINFEKL. To 
allow the correct processing of the OVA class I peptide, inserted in an exogenous context, both 
natural N-terminal and C-terminal flanking sequences (5aa each) were included (176) (Fig. 16a). 
ScFv-OVA257-264 recombinant molecules were produced in bacteria either as soluble proteins or 
displayed on phagemid and in eukaryotic cells (HEK 293T) by transient transfection. In this case, 
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the scFv-OVA DNA cassette was subcloned in the mammalian expression vector pcDNA3 (Fig. 
16b). Expression of the recombinant scFv-OVA257-264 (scFv-DEC205, scFv-2.4G2, scFv-CD36 and 
scFv-ctrl) proteins was evaluated by Western Blot analysis and functionality assessed by 






















Figure 16. Production of scFv-OVA257-264 recombinant proteins. Schematic representation of 
the DNA constructs that allow the production of scFv-OVA257-264 fusion proteins in bacteria (a) 
and eukaryotic cells (b). Western blot of scFv-OVA257-264 proteins produced by transient 
transfection in 293T cells, revealed with an anti-SV5 mAb (c). Binding of scFv-OVA257-264
proteins to splenic DCs, detected with a SIPanti-SV5 (d). 
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3.3.2 In vitro antigen cross-presentation assay using scFv-OVA257-264 proteins 
 To compare the ability of the different scFv-OVA257-264 fusion proteins to enter the cross-
presentation pathway, we initially performed in vitro cross-prentation assays using as antigen 
specific T cells the hybridoma B3Z. This cell line carries a β-galactosidase construct driven by the 
NF-AT element from the IL-2 promoter (177) and allows to measure the OVA-specific response 
either by evaluating IL-2 secretion or using chlorophenol red β-galactosidase (CPRG) as a substrate 
to detect LacZ activity in B3Z lysates. In these experiments, DCs were pulsed with different 
concentration of Ag before adding B3Z cells and co-cultured for 18 h before measuring LacZ 
activity. The assay was repeated several times, varying both the BM-DCs maturation state, the 
pulsing conditions (1-3h to o/n) and the form of the Ag used (soluble protein or recombinant phage). 
Despite the many conditions tested, we did not observed B3Z cells activation with any of the 
targeting scFvs (anti-DEC, anti-CD36 and anti-FcγR). Only the incubation of DCs with the peptide 
SIINFEKL or with a high concentration of soluble OVA (100 µg) resulted in B3Z activation (Fig. 
17a). 
 We reasoned that the lack of T cell proliferation may derive from the high threshold of 
activation of the of B3Z cells. We thus repeated the cross-presentation assay using CD8+ T cells 
isolated from OT-I mice, which carries a transgenic TCR (V 2/V 5) specific for the OVA 
SIINFEKL peptide restricted by H-2Kb (178). 
In this set of experiments, scFv-OVA257-264 proteins were produced by transient transfection in 293T 
cells. Supernatants containing the secreted recombinant proteins were dialyzed to get rid of peptides 
deriving from protein degradation and that could have been presented by DCs without direct 
processing. DCs were incubated with graded amount of scFv-OVA257-264 for 4 h and then washed. 
OT-I cells were co-cultured with DCs for 18 h before evaluating the expression of the T cell early 
activation marker CD69. Although in some experiments we detected OT-I activation by pulsing DCs 
with the scFvs targeting DEC-205, the FcγRs and CD36, but not with scFv-Ctrl, these data were not 
always reproducible (Fig. 17b). Collectively, these experiments were not sufficient to clearly 
evaluate whether Ags delivered via CD36 would access the cross-presentation pathway, yet they 
suggested that the OVA class I epitope could be correctly processed and presented when fused to the 
scFv. 
 The variability in the outcome and in the extent of the response may both derive from an 
imprecise quantification of the protein concentration or by the presence of products of degradation or 
contaminants in the cells supernatants used as Ag source. Notably, not all the recombinant scFv-
OVA257-264 proteins were produced with the same efficiency upon 293T transfection and indeed 
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protein quantification by Western Blot could not ensure that exactly the same amount of Ag was 
used in the assays. Several attempts were carried out to purify scFv- OVA257-264 proteins, either from 
bacteria periplasmic extracts or from cells supernatant by His6 tag affinity chromatography, but the 















Figure 17. In vitro targeting of DCs endocytic receptors by scFv-OVA257-264 
recombinant proteins. Activation of B3Z cells co-cultured for 18 h with DCs pulsed 
with an equal amount (100ng) of scFv-OVA257-264, soluble OVA (100µg) or OVA257-
264 peptide (1µM). CPRG was used as substrate to detect LacZ activity in B3Z lysates 
(a). Activation of OT-I cells co-cultured for 18 h with DCs pulsed with graded amount 
of scFv-OVA257-264 proteins. Expression of CD69 marker is taken as an index of OT-I 






3.3.3 In vivo antigen cross-presentation assay using scFv-OVA257-264 proteins 
 In parallel to the in vitro assays, we tested whether scFv-OVA257-264 proteins were able to 
target DCs in vivo and induce the activation of adoptively transferred OVA specific T cells (OT-I). 
scFv-OVA257-264 proteins (anti-CD36 or Control) were produced by 293T transfection and Western 
Blot was performed to estimate protein concentration by comparison to a previously quantified 
standard. 
OT-I T cells activation was assessed by flow cytometry either by evaluating CD69 expression at 
day1 post injection or by looking at the cell proliferation profile at day3. To track OT-I cells in vivo, 
we labeled them with the fluorescent dye CFSE, which allows each cell division to be visualized by 
flow cytometry as a sequential 2-fold reduction in fluorescent intensity. Labeled OT-I were 
adoptively transferred into congenic C57Bl/6 mice, followed by subcutaneous injection with 
comparable amount of scFv-OVA257-264 proteins. 
Although in some experiments the percentage of OT-I cells that underwent proliferation was higher 
in mice primed with scFv-antiCD36 respect to mice immunized with scFv-ctrl (Fig. 18a), these 
results were not reproducible. Moreover, the number of OT-I cells we tracked was too low to clearly 
evaluate the extent of T cell proliferation. 
In a second set of experiments, scFv-OVA257-264 proteins were injected intravenously and OT-I cells 
evaluated for CD69 expression. Despite several attempts, we were never able to detect a clear 
pattern of T cell activation (Fig. 18b). Collectively, these results are not sufficient to assess the 














Figure 18. In vivo targeting of DCs via CD36 by injection of scFv-OVA257-264 recombinant 
proteins. C57BL/6 mice were injected i.v. with 1x106 CFSE labeled OT-I cells and 
subsequently injected s.c. with an equal amount (200ng) of scFv-CD36-OVA or scFv-Ctrl-
OVA, as indicated. T cell proliferation was measured at day 3 in draining LNs. Dot plot 
represent the CFSE dilution profile of OT-I cells at day 3 (a). Mice were adoptively 
transferred with 1x106 OT-I cells and then i.v. injected with scFv-OVA257-264, as described 





3.3.4 Production of scFv-OVA fusion proteins 
 To improve the immunogenicity of our recombinant fusion proteins, we replaced the MHC 
class I OVA epitope with the full-length sequence of the antigen, which allows to evaluate in parallel 
the processing and presentation on both MHC class I and MHC class II molecules. We reasoned that 
the lack of a clear T cells activation profile upon immunization with scFv-OVA257-264 proteins may 
derive from the poor processing efficiency of the OVA class I peptide when directly fused to the 
scFv. This hypothesis was supported by the findings that even immunization with our positive 
control: scFvDEC-OVA257-264, did not always elicit efficient T cell priming. Secondly, lack of T cells 
activation may derive from the inefficient internalization of the scFv-CD36 molecule upon receptor 
binding. Indeed, some receptors such as FcRs require cross-linking to induce internalization. We 
thus engineered a dimeric variant of scFv-OVA protein which contained downstream of the scFv, 
the third constant domain of human IgG (SIP-OVA proteins) to induce CD36 cross-linking (Fig. 
19a). 
 The scFvs-OVA and SIPs-OVA were produced in 293T cells by transient transfection. 
Protein production and functionality were assessed by Western Blot and FACS analysis respectively 
(Fig. 19b and c). Notably, the expression of the different scFvs molecules by transfected cells was 
similar and protein concentration was estimated around 2-4 mg/litre. We next set up a protein 
purification protocol taking advantage of the His6 tag present at the C-terminus of the different 
forms of scFv/SIP-OVA molecules. Anti-His6 affinity chromatography was performed and protein 
concentration and purity was evaluated by SDS-PAGE and Comassie staining. We obtained pure 






















3.3.5 Internalization of SIP-CD36-OVA fusion protein 
 To initially study whether the SIP-CD36-OVA protein was endocytosed upon receptor 
binding, we performed a flow cytometry based internalization assay. DCs were incubated with SIP-
CD36-OVA or SIP-Ctrl-OVA at 4°C to allow receptor binding. Cells were then washed and 
incubated either at 4°C or 37°C for different time points (15 to 60 min). The amount of SIP-OVA 
remaining at the cell surface was evaluated by FACS using an anti-OVA Ab. As shown in Fig.25a, 
SIP-CD36-OVA was rapidly internalized with ~70% of the protein removed from cell surface within 
30 min at 37°C (Fig. 20a). 
We further confirmed this result by immunofluorescence analysis. Upon CD36 binding, cells were 
incubated at 4°C or 37°C for 30 min and SIP-CD36-OVA internalization was detected by anti-hIgG 
Ab. Data indicate that SIP-CD36-OVA was efficiently internalized at 37°C while it remained 









Figure 20. Internalization of the 
recombinant anti-CD36-antigen fusion.
Time course of SIP-CD36-OVA 
internalization. After binding at 4°C, DCs 
were incubated either at 37°C or at 4°C 
for the indicated time points. The plot 
shows the ratio of remaining surface-
bound scFvCD36-OVA at the two 
temperatures, measured with an anti-OVA 





Confocal microscopy of SIP-CD36-OVA internalization by DCs. After binding at 4°C, cells were washed 
and incubated for 30 min at 4 °C or 37°C, as indicated. Fixed and permeabilized DCs were stained with 
Alexa594-conjugated anti human Ab and FITC-conjugated cholera toxin subunit B, to counter stain plasma 
membranes. Images from the central Z-section of representative cells are shown (b). 
 
Figure 19. Eukaryotic expression 
of scFv-OVA and SIP-OVA 
recombinant proteins. Schematic 
representation of the monomeric 
scFv-OVA and dimeric SIP-OVA 
recombinant molecules (a). 
Western blot of recombinant Ag 
molecules detected with either 
anti-H6tag or anti-OVA Abs (b).
FACS analysis to evaluate binding 
of recombinant Ag proteins on 
WEHI cells, using an anti-OVA 
Ab (c). Western Blot and Comassie 





3.3.6 Role of CD36 in antigen presentation by targeting DCs in vitro 
 To investigate the capacity of SIPCD36-OVA to deliver OVA-derived peptide antigens to the 
MHC class I and MHC class II pathways of antigen presentation, we performed in vitro proliferation 
assays using as reporter cells OT-I or OT-II T lymphocytes. Whereas OT-I TCR is specific for 
OVA257-264 peptide, OT-II are transgenic for an MHC class II restricted αβTCR specific for the 
OVA323-339 peptide determinant presented in the context of MHC class II I-Ab (179). DCs isolated 
from the spleen of C57Bl/6 mice were incubated with graded concentration of the recombinant SIP-
CD36-OVA or SIP-Ctrl-OVA proteins or soluble OVA and then co-cultured with OT-I or OT-II 
cells. T cell proliferation was evaluated three days later by measuring [3H]thymidine incorporation. 
SIP-CD36-OVA induced OT-I and OT-II proliferation at a concentration as low as 20 ng/ml, 
whereas no proliferation was detected even at the highest concentration (1600 ng/ml) of SIP-Ctrl-
OVA. Relative to soluble OVA, uptake via CD36 increased the efficiency of presentation by at least 
400 fold for MHC class I epitope (Fig. 21a) and by 300-fold for MHC class II epitope (Fig. 21b). 
These results clearly demonstrate that targeting CD36 on splenic DCs increases the efficiency of 
presentation of protein antigens on MHC class II and, more importantly, is able to deliver OVA to 









Figure 21. In vitro targeting of CD36 on splenic DCs. Proliferation, measured as [3H]-
thymidine uptake, of OT-I cells (a) or OT-II cells (b) co-cultured for 72 h with spleen 
derived DCs pulsed with different concentrations of SIP-CD36-OVA (●), SIP-Ctrll-OVA 




 Previous data have shown that also B cells express high levels of CD36. We thus asked 
whether CD36 targeting on B cells leads to cross-presentation of OVA257-264 derived peptide. To 
compare the efficiency of cross presentation mediated by DCs versus B cells we isolated, from either 
spleen or lymph nodes, CD11c+ DCs, CD19+ B cells and CD11c- lymph nodes cells and pulsed them 
with different amount of SIP-CD36-OVA, SIP-DEC205-OVA or SIP-Ctrl-OVA. After 4 h, Ag was 
washed and pulsed APC were co-cultured with CFSE labelled OT-I cells. T cells activation and 
proliferation were assessed after 3 days by measuring secretion of IL-2 in the supernatants and by 
evaluating the CFSE profile by cytofluorimetry. Results show that only DCs are able to efficiently 
take up and present OVA to OT-I cell. Neither B cells nor DCs depleted lymph nodes cells 
stimulated T cell proliferation above the back-ground levels, even at Ag and cell doses 10-fold 
higher than those required to observe proliferation by DCs. SIP-Ctrl-OVA did not cause T cell 
activation even at the highest Ag dose (1µg). Splenic DCs pulsed with SIP-DEC205-OVA were 
twice as efficient than those pulsed with CD36 to induce T cells proliferation, whereas the same 
percentage of proliferated OT-I was observed in the case of DCs isolated from LNs and pulsed either 
with SIP-CD36-OVA or SIP-DEC205-OVA (Fig. 22a). These results were confirmed by measuring 
IL-2 production by ELISA. Only T cells primed by DCs secreted IL-2 (Fig. 22b) indicating that 





Figure 22. Cross-presentation by DCs and B 
cells. Proliferation of CFSE-labeled OT-I T 
cells, co-cultured for 3 days with 5x104 DCs 
(isolated from spleen or LNs), B cells (5x105) 
or CD11c-LN cells (5x105), pre-incubated with 
SIP-CD36-OVA (CD36), SIP-Ctrl-OVA (ctrl) 
or SIP-DEC205-OVA (DEC-205). Plots 
represent the percentage of OT-I cells that 
underwent proliferation (a). Production of IL-2 
(ng/ml) by OT-I cells primed by DCs or B 





3.3.7 In vivo targeting of DCs using SIP-OVA proteins 
 We next asked whether targeting antigen to CD11c+ CD8α+ DCs via CD36 is able to induce 
potent immune responses in vivo. 
At first, we investigated the ability of SIP-CD36-OVA to induce proliferation of OVA specific CD4+ 
T cells. Mice were adoptively transferred with CFSE labelled OT-II cells followed by immunization 
with graded doses of SIP-CD36-OVA or SIP-Ctrl-OVA. T cell proliferation was evaluated as CFSE 
dilution in the draining lymph node at day 3 upon injection. We detected OT-II proliferation only in 
lymph nodes of mice immunized with of SIP-CD36-OVA (200 ng) whereas priming with a higher 
amount of SIP-Ctrl -OVA (500 ng) did not elicit OT-II activation (Fig. 23). These data indicate that 
the recombinant antiCD36-OVA protein is able to target DCs in vivo and more importantly, it 





 We then focused on the ability to trigger cytotoxic T lymphocytes since this is particularly 
challenging for not replicating antigens and would be valuable for the design of effective vaccines.  
We compared the relative efficiency of scFv-CD36-OVA versus SIP-CD36-OVA to elicit OT-I 
activation in vivo. Mice, adoptively transferred with CFSE labelled OT-I cells, were immunized with 
equal amount of scFv-CD36-OVA, SIP-CD36-OVA or scFv-Ctrl-OVA. T cells proliferation was 
evaluated 3 days upon transfer by flow cytometry. Results show that immunization of mice with 
either the scFv-CD36 or SIP-CD36 OVA recombinant proteins, induced a similar extent of OT-I 
proliferation and accumulation at both doses tested (100-300 ng), whereas scFv-Ctrl-OVA 
completely failed to activate the CD8+ T cells response even at the highest Ag dose (Fig. 24a). These 
data indicate that targeting CD36 on DCs is a valuable means to enhance T cells priming in vivo and 
Figure 23. In vivo targeting of DCs via 
CD36 improves the efficiency of antigen 
presentation on MHC class II molecules. 
C57BL/6 mice were injected i.v. with 
1x106 CFSE labeled OT-II T cells and 
subsequently injected s.c. with graded 
doses of SIP-CD36-OVA or SIP-Ctlr-OVA 
T cell proliferation was measured at day 3 
in draining LNs. Histograms show one 
representative CFSE dilution profile of 
OT-II cells at day 3. 
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suggest that scFv-CD36 is efficiently internalized by DCs even without triggering the cross-linking 
of the receptor. 
 We next compared the OT-I response elicited by targeting DCs in vivo either via CD36 or 
DEC205. Mice were adoptively transferred with CFSE labelled OT-I cells and s.c. injected with 
increasing amounts of SIP-CD36-OVA, SIP-DEC205-OVA or SIP-Ctrl-OVA. Antigen specific T 
cell proliferation was determined in the draining lymph nodes at day 3 upon transfer. Practically all 
the OT-I cells in lymph node of SIP-CD36-OVA immunized mice entered cell cycle and underwent 
up to 6 divisions after a dose of just 100 ng of OVA protein, whereas immunization with a highest 
dose of SIP-Ctrl-OVA (300 ng) did not induce naïve OT-I cells to divide (Fig. 24b). We next 
compared the response elicited by targeting CD36 versus DEC205 and found that immunization with 
SIP-DEC205-OVA was more efficient in inducing entry in cycle since as little as10ng of protein 
induced extensive T cell proliferation (Fig. 24b). Collectively, these data indicate that although less 
efficient than DEC205, delivery of antigens through CD36 in vivo enhances the uptake and 










Figure 24. CD36-targeted antigen accesses the cross-presentation pathway in vivo. C57BL/6 
mice were injected i.v. with 1x106 CFSE labeled OT-I T cells and subsequently injected s.c. with 
graded doses of scFv-Ctrl-OVA, scFv-CD36-OVA or SIP-CD36-OVA (a), or with SIP-Ctrl-OVA,
SIP-CD36-OVA or SIP-DEC205-OVA (b), as indicated. T cell proliferation was measured at day 3 




3.3.8 Characterization of the CD8+ T cells response elicited by targeting CD36 on 
 DCs 
 We have shown that targeting CD8α+ conventional DCs through CD36 induces the active 
proliferation of adoptively transferred OVA specific CD8+ T cells. However, it is now clear that the 
effective presentation of the antigen and the subsequent T cell proliferation do not necessarily imply 
the induction of an immune response. Previous studies have in fact demonstrated that targeting 
immature, steady state DCs via DEC-205 results in the induction of peripheral tolerance rather than 
immunity. Although Ag specific CD8+ T cells initially expand upon DCs priming, they fail to 
differentiate in effector cytotoxic T cells and undergo a deletional mechanism (86). 
Therefore, procedures aimed at the induction of protective immune responses by targeting DCs in 
vivo, should in addition induce the activation of DCs in order to provide the T cells with the co-
stimulatory signals required for their differentiation into effector cells and the development of 
memory. 
 To evaluate the long-term effects of targeting Ags to CD36 receptor on DCs, we followed the 
fate of the OT-I cells that proliferated upon immunization with SIP-CD36-OVA and SIP-DEC205-
OVA, for comparison. To track the T cells in vivo, we isolated OT-I CD8+ cells from OT-I mice 
expressing a specific isoform of the CD45 marker (CD45.1) and adoptively transferred into C57Bl/6 
mice expressing the CD45.2 isoform. We next evaluated the number of OVA-specific T cells by 
means of an Ab that specifically recognizes the CD45.1 isoform. 
Mice were adoptively transferred with 2×106 OT-I cells and s.c injected with 300 ng of SIP-CD36-
OVA, SIP-DEC205-OVA or SIP-Ctrl-OVA either in the presence or absence of adjuvant (anti-CD40 
mAb) to induce DCs activation. At day 12 upon transfer, we evaluated the expansion of the antigen 
specific effector T cells in the spleen. In mice immunized with SIP-CD36-OVA in the absence of 
adjuvant we found a 2 to 3-fold expansion of OT-I cells, relative to mice injected with SIP-Ctrl-
OVA, or PBS. Notably, the co-administration of anti-CD40 mAb with SIP-CD36-OVA did not 
significantly increase T cell expansion. In contrast, immunization with SIP-DEC205-OVA, despite 
initial T cell proliferation, did not induce detectable expansion of antigen specific effector cells 
unless co-delivered with the anti-CD40 mAb (Fig. 25a). Still, T cell expansion was higher in mice 
primed with SIP-CD36-OVA than in mice immunized with SIP-DEC205-OVA plus adjuvant. 
Altogether these results indicate that, as already shown by previous works, antigen targeting to CD8+ 
DCs via the DEC205 receptor requires a maturation stimulus to induce immunity. Instead, targeting 
the same DCs subset via CD36 induces T cell expansion per se. 
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 To evaluate the effector functions of the OT-I cells present in the spleen at day 12 post 
injection, we monitored their capacity to produce IFN-γ upon in vitro restimulation with the OVA257-
264 peptide. In the absence of adjuvant, we detected a high proportion of IFN-γ secreting OT-I cells 
only in mice immunized with SIP-CD36-OVA. Moreover, the percentage of IFN-γ producing OT-I 
cells did not significantly increase when the Ag was co-administered with anti-CD40 mAb. In 
contrast, the few OT-I cells that persisted in mice primed with SIP-DEC205-OVA without adjuvant, 
were unable to secrete IFN-γ and were rescued only upon co-administration of anti-CD40 mAb 
(Fig.25b). 
To confirm the induction of effector OT-I cells upon targeting Ags to CD36, we performed an in 
vivo cytotoxicity assay. Mice were adoptively transferred with 1,5×106 OT-I cells and then s.c 
injected with 200 ng of SIP-CD36-OVA or SIP-Ctrl-OVA either with or without anti-CD40 
antibody. At day  12  after immunization, we injected a mixture of OVA peptide-pulsed and non-
pulsed syngeneic splenocytes to assess the cytolytic activity of in vivo primed OT-I cells. Effective 
cytotoxicity was observed only in lymph nodes and spleen of mice immunized with SIP-CD36-OVA 
regardless of the co-administration of anti-CD40. In mice primed with SIP-CD36-OVA ~90% of the 
peptide-pulsed targets were eradicated from lymph nodes, while a small proportion of target cells 
could still be detected in the spleen (Fig. 25c). Together, these data demonstrate that a single 
immunization with SIP-CD36-OVA is sufficient to induce a durable formation of effector memory T 






















Figure 25. CD36-targeting to steady state DCs induces long lasting cytotoxic T cells. 1.5 x106 
OT-I (CD45.1+) T cells were adoptively transferred into CD45.2+ C57BL/6 mice followed by 
immunization with 0,3µg of SIP-CD36-OVA, SIP- DEC-205-OVA or SIP-Ctrl-OVA, with or 
without the addition of anti-CD40 Ab (25µg). Spleens were harvested at day 12 to determine by 
flow cytometry: (a) the percentage of persistent CD45.1+ /CD8+ cells (OT-I) and (b) their ability 
to produce IFN-γ, following re-stimulation in vitro. (c) In vivo cytotoxicity assay. Mice were 
treated as above. The ability of primed OT-I cells to kill an Ag specific target cell was evaluated at 
day 12 by injecting mice with a mix of CFSE labelled syngeneic splenocytes pulsed (CFSEhigh) or 
not pulsed (CFSElow) with the OVA257-264 class I peptide. 15h post-injection, the ratio between 






3.3.9 Characterization of the endogenous T cells response elicited by targeting CD36 
 Having demonstrated the ability of SIP-CD36-OVA to induce priming and differentiation of 
adoptively transferred OT-I cells into effector memory T cells, we next sought to determine whether 
targeting OVA to CD36 could activate, as well, the endogenous naïve repertoire that contains low 
frequency of antigen-specific T cells. 
To this purpose, naïve C57Bl/6 mice were immunized twice in 14 days with 500 ng of SIP-CD36-
OVA or SIP-Ctrl-OVA. 7 days after the second immunization, lymphocytes isolated from blood 
were tested for the ability to produce IFN-γ upon in vitro restimulation with OVA257-264 peptide. As 
shown in figure 26a, mice injected with SIP-CD36-OVA, but not with SIP-Ctrl-OVA, developed an 
Ag specific CTL response as demonstrated by the percentage (4%) of IFN-γ secreting CD8+ T cells. 
In parallel, we examined the humoral immune response by measuring the titres of OVA-specific IgG 
antibodies by ELISA. High titres of anti-OVA specific antibodies were found in mice primed with 
SIP-CD36-OVA, but not with SIP-Ctrl-OVA indicating that targeting Ag to DCs through CD36 is 




Figure 26. Evaluation of the 
endogenous OVA specific T 
cell response. (a) Induction of 
OVA specific CD8+ T cells. 
Mice were immunized twice at 
1 week interval with an equal 
amount (0,5µg) of SIP-CD36-
OVA (CD36), SIP-Ctrl-OVA
(ctrl) or PBS. After 7 days,
lymphocytes isolated from 
blood were re-stimulated in 
vitro with the OVA257-264
peptide. Dot plots show one 
representative IFN- γ secretion 
profile in the different groups 
(left panel). Data expressed as 
means (n=3) of IFN- γ
secreting CD8+T cells (right 
panel). (b) OVA specific IgG 
Ab titers determined by ELISA 
from sera of animals 
immunized as in (a). Ab titre is 






3.3.10 Tumor protection experiments 
 We have demonstrated that targeting DCs via CD36 results in the effective induction of OVA 
specific cellular and humoral immunity. We next sought to determine whether the activation of the 
endogenous Ag-specific T cell response could confer protection against the graft of a OVA 
expressing tumour cells. As tumour model we chose E.G7 cells, a C57Bl/6 thymoma transfected 
with OVA cDNA which is insensitive to NK cell-mediated lysis and to anti-OVA mediated 
complement-dependent lysis (180) (181). 
C57BL/6 mice were immunized at day 0 and 7 with 500 ng of SIP-CD36-OVA or SIP-Ctrl-OVA 
and 7 days after the second immunization, mice were challenged by s.c injection of 2x105 E.G7-
OVA cells into the right flank. Tumour size was measured 2, 3 and 4 weeks after challenge. Results 
showed that immunization with SIP-CD36-OVA, increased the efficiency of tumour rejection and 
induced a significant delay in tumour growth compared to mice injected with SIP-Ctrl-OVA 
(p=0.0005). In contrast, immunization with SIP-Ctrl-OVA did not affect tumour rejection and up to 
100% of mice developed tumours comparable to not immunized mice (Fig. 27). 50% of mice primed 
with SIP-CD36-OVA remained tumour free after 40 days. Altogether these results demonstrate that 









Figure 27. Anti-tumor activity of endogenous T cells primed by 
CD36 targeted DCs. Growth of EG7-OVA tumor cells s.c injected in 
C57BL/6 mice not immunized (n=4) or s.c immunized (n=6) on day 0 
and 7 with 0,5µg of SIP-CD36-OVA or SIP-Ctrl-OVA. Tumor size was 
measured 14, 21 and 28 days after challenge. The average tumor size 
was expressed in cubic centimetres. Data shows one representative out 
























 Dendritic cells play a prominent role in the orchestration of a broad repertoire of immune 
responses. This led in the recent years, to the development of novel potential therapies aimed at 
harnessing DCs immunostimulatory properties for the treatment of chronic infections and cancer, or 
at silencing/reverting some of their functions during chronic inflammatory conditions, i.e 
autoimmunity or organ transplantation (182). 
The new concept of mobilizing the DCs system directly in situ, within their natural context, has 
proved feasible in animal models, upon the identification of receptors that are primarily expressed by 
DCs and the isolation of antibodies directed against these surface molecules. Recent studies have 
shown that immunization with antigens coupled to antibody that are directed against DCs endocytic 
receptors greatly increases the efficiency of antigen presentation on both MHC class I and MHC 
class II molecules and results in the induction of antigen specific T cell mediated and humoral 
responses (27, 129, 145, 150). So far, these targeting studies have revealed that the efficacy of in 
vivo DCs vaccination depends on numerous factors that are related not only to the nature and 
biological properties of the receptor targeted, but also to the specific DCs subset that expresses the 
receptor (127-129) and on the maturation or activation status of the DCs (85, 86). Besides the 
intrinsic nature of the receptor and the DCs subset targeted, a second factor that likely affect the 
outcome of the immune response is related to the selection of an appropriate antibody/receptor 
pairing. For instance, antibodies directed against the same receptor, but recognizing different 
epitopes or domains, may differ in their internalization potential and as a consequence, in the amount 
of antigen delivered into the cell compartments involved in antigen processing (183). 
 
 Based on these observations, it is difficult to predict which strategy among the proposed ones 
is the most efficient on a comparative basis. Thus, there is the necessity to identify new receptors, 
characterize their mode of action and develop technologies that facilitate comparative studies. 
With the aim to improve current existing strategies we set up a screening of phage-displayed 
libraries of Ab fragments (scFv) on DCs. Whole-cell panning screening is a powerful technique in 
that it provides new Ab candidates that recognize antigens in their native conformation, an essential 
requirement for their in vivo application, and it allows the isolation of Abs that trigger a specific 
biological function (i.e. internalization). In addition, once the phage carrying the scFv with the 
desired specificity is identified, its sequence can be isolated and modified to create fusion proteins 
that include antigenic epitopes. This provides us with an easy and rapid method to test new 
endocytic receptors for antigen presentation. Finally, recombinant scFv proteins can be produced in 
large amount and subsequently used to identify their cognate receptors. 
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In this study we provide the proof of principle of such methodology. This is the first report that 
describes the successful isolation of internalizing antibodies by phage display on mouse dendritic 
cells and it thus provides the rationale for the further development of such a promising technology 
(i.e. screening performed on specific dendritic cells subsets or on dendritic cells of human origin). 
 
 The initial part of this work has focused on the setting up and optimization of the phage 
screening procedure. We identified some parameters that are important for the enrichment of phages 
that specifically bind to DCs (i.e. blocking solution and washing conditions) and are crucial for the 
preferential recover of endocytosed phage particles (i.e. internalization time and treatment of the 
cells with subtilisin). Our results show that we successfully applied a procedure to select, from a 
filamentous phage display library, scFvs Ab fragments internalized by DCs. The fact that after three 
rounds of panning we recover a pool of phages characterized by similar hypervariable regions, 
suggests that the conditions under which the screening has been performed may be too stringent, 
leading to the isolation of the scFv-phage particles with the highest affinity and internalization 
potential. Therefore, a reduction in the number/stringency of the washings may lead to the isolation 
of a greater number of different clones. Further analysis of the scFv sequences recovered after two 
rounds of panning may indeed support this hypothesis. Alternatively, the limited set of scFv-clones 
may be the result of a bias in the original scFv-phage library. A higher frequency in the original 
library or a greater stability of these scFv-phagemid may have conferred a growth advantage and 
thus favored their amplification in each round of selection.  
 
 The selected Ab fragments showed a peculiar binding profile on DCs, with only a percentage 
of the cells staining positively (Fig. 11). We reasoned that this feature was particularly relevant, 
considering the heterogeneity of the DCs population isolated from mouse lymphoid organs (4) and 
the specific roles that these DCs subsets play in the initiation of different type of immune responses 
(3). 
We thus focused on the characterization of a dominant clone, scFv-2E5. We demonstrated that it 
recognizes a putative receptor primarily expressed by the CD8α+ subset of lymphoid organ DCs 
(Fig. 14a). Thanks to the high affinity of scFv-2E5 for its ligand and taking advantage of standard 
biochemical techniques coupled to mass spectrometry analysis, we were able to identify the 
molecule recognized by scFv-2E5 as the mouse scavenger receptor CD36 (Fig. 15). 
The finding that other scFvs sharing a sequence similarity in the CDR H3 region did recognize the 
same receptor, whereas scFv 9 which carry a different sequence did not, suggests that the last 5 aa in 




 CD36 belongs to the class B scavenger receptor family. It has been implicated in multiple 
biological processes that define it as a multiligand scavenger receptor (34). CD36 was shown to be 
expressed on DCs and cells of hematopoietic origin, including platelets and macrophages, but also 
on microvascular endothelium, adypocytes and muscle cells. Our results confirm the unique 
distribution pattern of CD36 among DCs, its preferential expression on the CD8α+ splenic DCs (25, 
26), and further demonstrate its lack of expression on Langherhans, interstitial and plasmacytoid 
DCs (Fig.14). We also detect CD36 on macrophages and on a percentage of B cells, where its 
expression was shown to correlate with the expression level of the B-cell differentiation factor Oct-2 
(184). 
CD36, until recently best known as a receptor for thrombospondin-1 (TSP-1), also bind long-chain 
fatty acids (185), modified LDL (186), anionic phospholipids (38), uric acid (187) and collagen I and 
IV. It is reported to play a role in diverse cellular processes including foam cell formation (188), 
fatty acid transport (189) and suppression of angiogenesis (190).  
CD36 has also been implicated in the innate immune response to GRAM+ bacteria such S. aureus . 
Hoebe et al first demonstrated the selective and nonredundant role of CD36 as sensor for microbial 
diacylglycerides. Upon binding to bacterial lipoteichoic acid (LTA), CD36 forms a cluster with the 
heterodimer TLR2/TLR6 within lipid raft, followed by the internalization of the complex. These 
data collectively indicated that CD36 acts as a facilitator or co-receptor for diacylglyceride 
recognition through the TLR2/6 complex (40). Due to these multiple functions, it would be 
interesting to map the epitopes recognized by the various scFvs directed against CD36 and test 
whether they are able to prevent the binding of the natural ligands or alter some of the biological 
functions of the receptor. 
Few studies have addressed the role of CD36 in APCs. At first, CD36 was shown to be involved in 
the engulfment and removal of apoptotic cells in human DCs (24) implicating its possible role in the 
cross-presentation of antigens derived from apoptotic bodies. However, subsequent studies indicated 
that CD36 is not essential for either cross-priming nor cross-tolerance since CD36-/- APC were fully 
competent to carry out cross-presentation of Ags derived form apoptotic cells in vivo (25, 26). Most 
recent data suggest that CD36 is selectively implicated in the presentation of Ags derived from 
apoptotic bodies on MHC class-II molecules. Janssen et al. demonstrated that in Oblivious mice, 
which carry a nonsense allele of Cd36 and are equivalent to CD36-/- mice, the CD4+ T cell response 





 In the present work we show a new function for CD36 receptor in adaptive immunity. 
We produced an antibody based vaccine, by rescuing the sequence that code for the variable regions 
of the scFv directed against CD36 and fused them to an antigenic unit. As model antigen we chose 
ovalbumin due to the availability of systems that easily allow to evaluate the presentation of MHC 
class I and MHC class II epitopes to antigen specific T cytotoxic (OT-I) and T helper (OT-II) 
lymphocytes. We show that targeting an Ag to DCs via CD36 results in its rapid internalization (Fig. 
20) and mediates its processing and presentation on both MHC class I and MHC class II molecules. 
In vitro, CD36-mediated uptake allows the efficient presentation of Ags found at nM concentration 
(Fig. 21). In addition, we show that this property is unique of DCs since B cells, that express the 
receptor and bind the recombinant antibody, were unable to cross-present the OVA epitope to T cells 
and thus trigger T cells proliferation (Fig. 22). 
Most importantly, we showed that our recombinant scFv is able to target DCs in vivo. Immunization 
of mice with a low amount (0,1µg) of SIP-CD36-OVA elicits extensive proliferation of adoptively 
transferred antigen specific CTL and TH lymphocytes (Fig. 23-24). 
Remarkably, CD36 can be successfully targeted through a monovalent single-chain antibody. We 
show that targeting with the dimeric form of the recombinant antibody (SIP) did not apparently 
increased the efficiency of antigen presentation and the extent of OVA specific CD8+ T cells 
proliferation, indicating that the cross-linking of the receptor is not required to induce its 
internalization. 
 
These data clearly indicate that targeting antigens to CD36 elicits both CTL and TH responses. This 
means that upon internalization, the antibody/receptor complex follows an intracellular route that 
allows the antigen to gain access to both MHC class I and MHC class II loading compartments. 
CD36-TLR2/6 heterocomplex has been shown to target the Golgi compartment upon binding and 
internalization of bacterial derived lipoteichoic acids (41). Whether CD36 follows a similar route 
upon targeting with the scFv-OVA protein, remains to be established. 
It has been described that the mechanisms of Ag uptake can dictate the intracellular destination 
compartment and thus determine the presentation of Ag to CD4+ and/or CD8+ T cells. For instance, 
pinocytosis conveyed OVA to lysosomes for MHC class II-restricted presentation, whereas mannose 
receptor mediated endocytosis results in the delivery of ovalbumin into stable early endosomal 
compartment that eventually lead to cross-presentation (126). Moreover, the fate of an antigen 
captured by receptor mediated endocytosis will depend on the specific intracellular route followed 
by the receptor. For example, the mannose receptor is predominantly found in early endosomes, 
whereas DEC205 recycle through late endosomal compartments, property that seem to be crucial for 
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the presentation of antigens on MHC class II molecules (192). To date, there are no reports 
describing the specific recycling route followed by CD36. We are therefore performing co-
localization studies using early endosomes and lysosomes specific markers to map the internalization 
pathway of the scFv-OVA/CD36 complex. However, it has to be kept in mind that the intracellular 
routing of a receptor may also be influenced by the targeting moiety and so by the specific epitope 
engaged by the antibody or ligand. For example, dectin-1 recycles to the cell surface after binding 
laminarin, but not after binding glucan phosphate (193). Therefore, the route followed by scFv/CD36 
complex will not necessarily be the same of that followed by the receptor upon binding with other 
ligands. 
 
 The type of immune response elicited by targeting different endocytic receptors on DCs may 
depend on the specific DCs subset that expresses the receptor. For instance, antigens delivered to 
receptors on mouse CD8+ DCs are presented preferentially to CD8+T cells, whereas antigens 
targeted to CD8- DCs are able to mediate strong CD4+ T cell responses. 
Ags captured via the C-type lectin DEC205 and the mannose receptors that are both CD8α+ specific 
are cross-presented. We provide evidences of a further CD8α+ specific receptor, CD36, that induces 
cross-presentation of endocytosed Ags.  
Among lymphoid-organ resident DCs, those expressing the CD8α marker are clearly the most 
efficient at cross-presenting cellular (119), soluble (121, 122) and pathogens associated Ags (59, 
124). The ability of CD8α+ DCs to process exogenous Ags for presentation on MHC class-I 
molecules may thus depend on the expression of a specialized pathway to promote the generation of 
MHC class-I peptides from internalized Ags. Thus it is tempting to speculate that targeting any 
endocytic receptors on CD8α+ would deliver the antigen to this specialized machinery and so lead to 
cross-presentation. 
Although the dichotomy between CD8+ and CD8- DCs well describe the effects elicited by targeting 
Ags to receptors such as DCIR-2 (127), dectin-1 (128), CIRE and FIRE (129) on CD8- DCs, this 
paradigm may be an over-simplification and may lead to the erroneous view that CD8+ DCs are not 
so efficient in priming TH lymphocytes.  
In the present work we demonstrate that targeting CD36 on CD8+ DCs results in the formation of 
both MHC-I and MHC-II/peptide complexes and thus in the active proliferation of both CD8+ and 
CD4+ T lymphocytes. Most importantly, we show that immunization of mice with the recombinant 
scFvCD36-OVA protein induces a strong anti-OVA antibody response (Fig. 26b), indicating that 
CD8+CD36 targeted DCs can trigger both arms of the immune system. 
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Several studies have shown that targeting DEC205 on CD8+ DCs elicits weaker CD4 T cell 
responses respect to DCIR-2 or dectin-1 on CD8- DCs (127, 128). However, this effect may be a 
peculiar property of DEC205 and be related to the intracellular pathway followed by the antigen 
upon receptor internalization. DEC205 is indeed very efficient in delivering antigen to the MHC 
class I presentation pathway, and we also show, in a comparative study, that targeting this C-type 
lectin receptor is more efficient in inducing OT-I activation than CD36 (Fig. 24b). It is tempting to 
speculate that upon internalization via DEC205, the majority of the antigen is delivered to the MHC 
class I loading compartment, leaving only a minor amount available for MHC class II presentation. 
The situation may be different in case of antigen captured via CD36, where probably a higher 
amount of endocytosed protein remains available for MHC class II loading. Therefore, a direct 
comparison of the efficiency of DEC205 and CD36 to activate antigen specific CD4+ T cells it is of 
crucial importance to better elucidate the properties of the lymphoid organ resident CD8+ DCs. 
 
 The capacity of CD36 to deliver antigens to the MHC class I loading compartment is 
particularly valuable, since it makes this scavenger receptor a good candidate for vaccination 
strategies aimed at generating potent cellular responses directed against tumours or pathogens that 
are inefficiently cleared by the humoral immune system. 
Our results show that targeting low amount of antigen to DCs via CD36 not only results in the 
activation of large numbers of TCR-transgenic T cell is vivo, but it is also able to prime the 
endogenous naïve repertoire that contains a low frequency of antigen/specific T cells (Fig. 26a). A 
second major concern when designing a DCs based vaccination strategy, derives from the necessity 
to deliver the antigen coupled to a maturation signal, since mere targeting of antigens to DCs 
receptors without providing proper activation may result in tolerance in mice (85, 86). These 
findings are consistent with DC-based therapy studies in humans showing that DC maturation is a 
pre-requisite for the induction of immunity (194). 
The C-type lectin DEC205 has been the prototype target receptor to induce immune responses 
against various Ags (144, 146, 159). Induction of protective cellular immunity via DEC205 
however, required the systemic administration of a second maturation signal in the form of CD40-
specific antibody to mimic T cell help. Some receptors such as TLR2, TLR4 and CD40 or FcγRs 
have an inherent capacity to mature DCs, so that targeting vectors directed against these molecules 
do not necessitate the addition of adjuvants to induce immunity (143, 149, 150, 195). Moreover, 
targeting antigens to DCs receptors like CIRE and FIRE results in the induction of humoral 
immunity in the absence of additional "danger" signals, even though receptor engagement does not 
seem to directly activate DCs. 
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In the present study, we demonstrate that when antigens are targeted to DCs through CD36 such 
additional maturation signal is dispensable to generate long lasting protective immune responses. 
Specifically, immunization of mice with SIPCD36-OVA, in the absence of CD40 adjuvant effect, 
induces the differentiation of adoptively transferred CD8+ T cells into long term effector cells (Fig. 
25) and more importantly elicits an immune response that protect mice in tumor graft experiments 
(Fig. 27). Thus, it is tempting to speculate that CD36 provides per se a DCs maturation signal. A 
recent work by Urban et al. demonstrated that CD36 ligation on mouse DCs increases the 
production of the immunomodulatory cytokine TGFβ,  but do not directly up-regulates the 
expression of co-stimulatory molecules (196). It would be interesting to investigate whether 
triggering of CD36 with our scFv molecule results in the activation of a similar signaling pathway, 
or whether the engagement of CD36 in our model may activate pro-inflammatory responses by co-
engaging TLRs at the cell surface, as shown to occur during the uptake S. aureus (42). 
Alternatively, the immune response observed in mice vaccinated with SIP-CD36-OVA may be 
modulated by other cell types that express the receptor. Although we demonstrate that only DCs are 
able to cross-present OVA captured via CD36 (Fig. 22), this does not rule out an involvement of 
other APCs, especially B cells, in the presentation of OVA epitopes to CD4+ T cells. As a last 
possibility, processing of Ags internalized via CD36 may be less selective in consuming Ags for the 
MHC class I pathway thus leaving it available for the class-II pathway. This would lead to more 
efficient CD4+ T cell activation bypassing the need of adding exogenously the help provided by the 
anti CD40 Ab. In favor of these last two hypothesis is the fact that immunization via CD36 induces 
also high levels of Ag specific Abs (Fig. 26b). Collectively, these data indicate that targeting an Ag 
to CD36 in vivo is a novel approach to initiate protective immune responses and may represent a 























 In this work we provide the proof of concept that screening of antibody libraries on DCs is a 
powerful tool to identify new antibody/receptor pairings of potential clinical interest. This is the first 
report that describes the successful application of the phage display technology to isolate 
internalizing antibodies on mouse dendritic cells and it thus provides the rationale for the design of 
novel phage screening directed against specific subsets of murine DCs or DCs population of human 
origin. 
In the present study, we focus on the properties of a selected high affinity antibody directed against 
CD36, a CD8α+ DCs specific receptor whose role in the induction of immune responses is still 
unclear. Using a recombinant anti-CD36 Ab fused to ovalbumin we demonstrate that in vitro 
targeting of DCs via CD36 results in the processing and presentation of the antigen on both MHC 
class I and MHC class II molecules. Moreover, we show that in vivo delivery of OVA to DCs 
through CD36 elicits the active proliferation of adoptively transferred CD4+ and CD8+ antigen 
specific T cells and the differentiation of CTLs into long-term effector cells. Remarkably, such a 
response is induced in the absence of any added DCs maturation stimulus and thus it differs from 
that triggered by the targeting of DEC205 receptor, the golden standard to target CD8α+ DCs. 
Finally, we demonstrate that immunization of mice with the recombinant anti-CD36 Ab fused to 
OVA is able to prime the endogenous pool of antigen specific CD8+ T cells, induces the production 
of anti-OVA antibodies and confers protection against an OVA expressing tumor, in the absence of 
any additional adjuvancy. 
Collectively, these data are of interest for the fundamental understanding of CD8α+ DCs biology and 
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